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ABSTRACT
Chronic inflammation in adipose tissue has been demonstrated to play an
important role in the pathogenesis of insulin resistance. The infiltration of immune cells
results in a significant increase of pro-inflammatory cytokines in adipose tissue that
substantially affects adipocyte function. Lipocalin-2 (LCN2) is an adipocyte-secreted
cytokine whose expression and secretion has been shown to be induced in obesity and
insulin resistance in mouse and man. However, the underlying mechanisms have not
been explored. Our studies indicate that interferon-gamma (IFNγ) and tumor necrosis
factor-alpha (TNFα), two primary pro-inflammatory cytokines secreted from immune
cells, can induce LCN2 expression and secretion from adipocytes both in vivo and in
vitro. Mechanistic studies reveal that IFNγ modulates LCN2 expression via STAT1 and
ERKs signaling pathways, while NF-κB and ERKs pathways mediate the actions of
TNFα on LCN2 expression. Inhibition of ERKs activation attenuates the induction of
LCN2 without significant effects on either the nuclear translocation or DNA binding
activity of STAT1 and NF-κB. Further experiments show that pharmacological ERKs
inhibition disrupts the serine phosphorylation of STAT1 and NF-κB p65 subunits, and
reduces transactivation activity of both of these transcription factors. Moreover, we
identified several STAT1 and NF-κB binding sites in both the murine and human LCN2
promoters. Overall, these studies enhance our knowledge regarding the requirements
and mechanisms used by pro-inflammatory cytokines to induce LCN2 expression.
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CHAPTER 1. GENERAL INTRODUCTION
1.1 Adipose Tissue, Obesity and Insulin Resistance
Adipose tissue is an organ that consists of adipocytes and a stromal vascular
fraction that contains preadipocytes, endothelial cells, and mesenchymal stem cells.
Recent studies of adipose tissue have revealed that various immune cells can infiltrate
into adipose tissue (1). Adipose tissue, skeletal muscle and liver are the three primary
insulin sensitive tissues in the body. These tissues respond to insulin to regulate
circulating glucose levels and maintain energy homeostasis. Insulin-stimulated glucose
uptake in adipose tissue and skeletal muscle is essential for controlling blood glucose
levels. In pathological conditions, insulin-sensitive tissues are often unresponsive to
insulin because of disruptions in insulin signaling. This condition is referred to as insulin
resistance, a major health risk that is associated with hypertension, cardiovascular
disease and metabolic syndrome (reviewed in (2)).
Adipocytes are one type of specialized cells in vertebrates. Adipocytes were
initially known for their lipid storage function. However, studies in the past two decades
have demonstrated that adipocytes play key roles in the regulation of energy
homeostasis and systematic insulin sensitivity. Adipocytes have been demonstrated to
have three important functions. Fat cells are the warehouses for lipid storage; they
produce cytokines and hormones that modulate energy metabolism; and they are highly
sensitive to insulin (reviewed in (3)). It is known that three important hormones, leptin
(4), adiponectin (5) and resistin (6), are exclusively produced from adipocytes or
adipose tissue in mice and humans. Leptin plays an essential role in the regulation of
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food intake and energy balance (4). Adiponectin is critical for maintaining insulin
sensitivity (5) and resistin is related to the pathogenesis of insulin resistance (6).
Disruption of any one of the three primary functions of adipocytes can result in the
disturbance of metabolic homeostasis and insulin resistance.
Currently, most of our knowledge about adipocytes comes from studies
performed in cultured cell lines. The most used adipocyte-like cell lines are the 3T3-L1
and 3T3-F442A cells, both of which were cloned from the cultured murine embryonic
fibroblast cell line 3T3. Howard Green and his colleagues at Harvard University
separated the 3T3 cells that accumulated lipid after confluence to establish these two
cell lines (7;8). Both 3T3-L1 and 3T3-F442A preadipocytes still have the capability to
proliferate in growth media. However, once they are confluent, they are induced with a
cocktail of hormones (isobutyl-methylxathine, dexamethasone and insulin) that
promotes their exit from the cell cycle and differentiation into mature adipocytes (9).
Obesity is a disease characterized by excess adipose tissue in the body that is
caused by positive energy balance. Obesity has become a world-wide epidemic disease
and affects more than 30% of adults in the United States (10). Plenty of evidence
suggests that metabolically unhealthy adipose tissue in obese individuals plays a critical
role in the occurrence of insulin resistance. Several metabolic pathways in adipocytes
including glucose uptake, lipogenesis and lipolysis are significantly affected by insulin
action. GLUT4 is an insulin-stimulated glucose transporter expressed in adipose tissue,
skeletal muscle and heart. Under basal conditions, GLUT4 is stored in cytoplasmic
vesicles. Upon stimulation with insulin, GLUT4 translocates to the cell membrane, and
transports glucose molecules into cells (reviewed in (11)). However, in insulin-resistant
2

subjects, insulin-stimulated glucose uptake is impaired because of the inhibition of
insulin signaling. A significant reduction of insulin-stimulated glucose uptake ultimately
results in an increase of circulating glucose in insulin resistant and diabetic subjects
(reviewed in (12)).
1.2 Pro-inflammatory Cytokines in Adipose Tissue
Pro-inflammatory cytokines are important immune response mediators that can
induce both acute and chronic inflammation. These cytokines are largely secreted from
immune cells, including macrophages, cytotoxic T cells and natural killer cells (13;14).
Prior to studies that revealed the connection between inflammation and insulin
resistance in adipose tissue, there was substantial evidence to indicate that proinflammatory cytokines can induce insulin resistance (15). In 2003, chronic inflammation
and infiltration of immune cells in adipose tissues was shown to be a critical player in
obesity-related insulin resistance (1;16). It was demonstrated that macrophages could
infiltrate into white adipose tissues (WAT) of obese subjects, and affect the
physiological functions of adipose tissues (1). The pro-inflammatory cytokines secreted
from immune cells are substantially increased in adipose tissue of obese and diabetic
animal models (1;16). Previous studies have reported that the pro-inflammatory
cytokines affect the three primary functions of adipocytes. TNFα and IFNγ have been
shown to inhibit lipogenesis in adipocytes (17;18). Several pro-inflammatory cytokines,
including TNFα (15), IFNγ (19) and IL-1β (20), have been known to disrupt insulin
signaling and induce insulin resistance. Pro-inflammatory cytokines also have the
capability to affect gene expression in mature adipocytes. Expression of PPARγ and
adiponectin, two important modulators of insulin sensitivity, are reduced by pro3

inflammatory cytokines (21;22). Also, pro-inflammatory cytokines induce the expression
and secretion of chemokines (23-25), which recruit more immune cells into adipose
tissues. Hence, the actions of pro-inflammatory cytokines affect the physiological
functions of adipocytes and adipose tissue.
TNFα
Tumor necrosis factor-alpha (TNFα) is an important pro-inflammatory cytokine
produced from monocytes and macrophages (13). TNFα is well known for its ability to
mediate immune response (26), apoptosis (27) and autophagy (28). In addition, TNFα
can be produced from macrophages that infiltrate into adipose tissue (1;29). Expression
of TNFα significantly increases in adipose tissue of obese and insulin-resistant
individuals (30;31) due to its production in adipose tissue macrophages. The elevation
of TNFα is attenuated by decreases of body weight, which also increases insulin
sensitivity (30).
As the first cytokine that was recognized to induce insulin resistance in
adipocytes, TNFα was shown to repress transcription of glucose transporter GLUT4 (32)
and expression of insulin receptor (IR) and insulin receptor substrate-1 (IRS-1) in
cultured 3T3-L1 adipocytes (33). Tyrosine phosphorylation of IR and IRS-1 is required
for activation of insulin signaling in adipocytes (34), while serine phosphorylation of IRS1 prevents activation of insulin signaling (35). TNFα has been reported to disrupt insulin
signaling via inhibiting insulin-stimulated tyrosine phosphorylation of IR and IRS-1
(15;36) and inducing serine phosphorylation of IRS-1 (35;37) in cultured adipocytes.
Peroxisome proliferator-activated receptor-gamma (PPARγ) (38) and adiponectin (39)
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are two well-known positive regulators of insulin sensitivity. The expression of both
PPARγ (22) and adiponectin (40) has been found to be suppressed by TNFα. In
addition, TNFα has been demonstrated to repress PPARγ activity via inducing cyclindependent kinase 5 (CDK5)-mediated phosphorylation on Serine 273 residue (41). In
vivo studies have reported that TNFα administration impairs insulin sensitivity and
reduces insulin-stimulated glucose uptake in humans (42;43). Neutralization of TNFα in
obese fa/fa rats significantly increases tyrosine phosphorylation of IR and IRS-1 (44). To
further clarify the roles of TNFα in vivo, TNFα knockout mice were created to study the
influence of TNFα deficiency on insulin sensitivity. TNFα-deficient DIO (diet induced
obesity) and ob/ob (leptin deficient) mice exhibited a significant improvement of insulin
sensitivity compared to normal DIO and ob/ob mice (45). The inhibition of insulin
signaling in both DIO and ob/ob mice was attenuated by the deficiency of TNFα (45).
Both in vitro and in vivo studies provide evidence that TNFα contributes to the
occurrence of obesity-related insulin resistance.
IFNγ
Interferon-gamma (IFNγ) is the only member of the type 2 interferon family and
has important roles in immune responses to viral infection (46). IFNγ can be secreted
from lymphocytes, NK cells, B cells, and antigen-presenting cells (APCs) to activate
cell-specific immunity and cytotoxic immunity during viral infection (14). In obese and
insulin resistant conditions, IFNγ is produced and secreted from the immune cells that
infiltrate into adipose tissue (47). A previous study has shown that high-fat diet
increases IFNγ production in adipose tissues (48). Human studies have revealed that
IFNγ is highly up-regulated in obese individuals (49).
5

In 1998, hyperglycemia and insulin resistance was reported in humans with IFNγ
therapy (50). Studies of adipocytes provided evidence that IFNγ plays essential roles in
the occurrence of insulin resistance. IFNγ administration impairs insulin-stimulated
glucose uptake in both murine and human adipocytes (19;51). Insulin signaling was
inhibited by IFNγ treatment via reducing expression of IR, IRS-1, GLUT4 and
phosphorylation of Akt (51). In human adipocytes, the expression of PPARγ and
adiponectin is also inhibited by IFNγ treatment (51;52). Mechanistic studies in our group
demonstrated that IFNγ reduced PPARγ levels in 3T3-L1 adipocytes by inhibiting
PPARγ expression (53) and inducing ubiquitin-proteasome dependent degradation of
PPARγ (54). Also, IFNγ has been reported to suppress normal lipid accumulation and
adipocyte development (55;56). In mature adipocytes, IFNγ was also found to inhibit
lipoprotein lipase activity and lipid storage (18). The prevention of lipid storage in
adipocytes and decreased expandability of adipose tissue could result in ectopic lipid
storage in other tissues, such as the liver. Ectopic lipid storage is considered to
contribute to the pathogenesis of insulin resistance (57). Consistent with cell culture
experiments, animal studies also suggest a role of IFNγ in the pathogenesis of insulin
resistance. IFNγ deficiency attenuates inflammation in adipose tissues and modestly
improves insulin sensitivity in DIO mice (58).
Other pro-inflammatory cytokines
As major pro-inflammatory cytokines, there is substantial evidence that TNFα
and IFNγ have important effects on adipose tissue in obese and insulin resistant
subjects. However, besides TNFα and IFNγ, there are other pro-inflammatory cytokines
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that can also modulate of insulin sensitivity. These include interleukin-6 (IL-6),
plasminogen activator inhibitor-1 (PAI-1), and interleukin-1β (IL-1β).
Interleukin-6 (IL-6) is a member of the gp130 cytokine family. It is estimated that
10-35% of plasma IL-6 is produced from adipose tissue (59). The expression and
secretion of IL-6 is highly induced in adipocytes of insulin-resistant individuals (60).
Circulating IL-6 is significantly increased in obesity and insulin resistance (31). However,
the effects of IL-6 on insulin sensitivity are still controversial. Studies in cultured
adipocytes reported that chronic treatment of IL-6 inhibits expression of insulin signaling
proteins IR, IRS-1, glucose transporter GLUT4 (61), and proteins associated with insulin
sensitivity such as adiponectin (62) and PPARγ (63). Another study showed that IL-6
up-regulated expression of the inflammatory marker monocyte chemotactic protein-1
(MCP-1) (64). A study in humans indicated that IL-6 administration significantly
increases plasma glucose level in a dose-dependent manner (65). Animal experiments
have demonstrated that chronic IL-6 treatment at pathological concentrations in obesity
could inhibit the phosphorylation of IR and IRS-1&2 in liver (66), but had no effect on
insulin signaling in adipose tissue of mice (67). Yet, other studies demonstrated positive
effects of IL-6 on insulin sensitivity. In skeletal muscle, IL-6 expression has been
reported to be induced by exercise (68). IL-6 treatment increases AMPK activity and upregulates expression of AMPK target genes (69). AMPK activity is impaired in skeletal
muscle and adipose tissue of IL-6 knockout mice (69). Other studies showed that highfat diet (HFD) fed IL-6-deficient mice had more severe hepatic insulin resistance and
inflammation than wild-type mice fed with HFD (70). Hence, the role of IL-6 in insulin
action is confusing and controversial.
7

Plasminogen activator inhibitor-1 (PAI-1) was identified for its roles in fibrosis
during inflammation. PAI-1 is mainly expressed in the endothelium, but can also be
produced and secreted from both preadipocytes (71) and mature fat cells (72;73).
Circulating levels of PAI-1 are positively related to body mass index (BMI) (74), and
significantly elevated in subjects with metabolic syndrome (75) and insulin resistance
(76). PAI-1 deficient mice are protected from HFD-induced insulin resistance (77). The
decrease of PPARγ and adiponectin expression that normally occurs in HFD-fed mice
was attenuated by PAI-1 knockout (77). Plasma free fatty acid (FFA) and TNFα levels
were also down-regulated by PAI-1 deficiency (78). Although the signaling pathway
utilized by PAI-1 is still uncovered, there is substantial evidence that PAI-1 is a novel
mediator of obesity-induced insulin resistance.
Interleukin-1β (IL-1β) is mainly produced from monocytes, macrophages and
dendritic cells. IL-1β plays important roles in the occurrence of chronic inflammatory
diseases (79). Expression of IL-1β in adipose tissue is elevated in obesity-related insulin
resistance (80). In cultured adipocytes, IL-1β has been found to inhibit insulin-stimulated
glucose uptake and lipogenesis via attenuating insulin-induced phosphorylation of IR
and IRS-1 (20). Expression of glucose transporter GLUT4 (81) and adiponectin (52) is
also repressed by IL-1β treatment. Animal studies have shown that IL-1β administration
increases hepatic glucose production, decreases glucose deposit, and induces insulin
resistance (82). Collectively, these results suggest that IL-1β also plays a role in insulin
resistance in adipocytes.
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1.3 Signaling Pathways in Adipocytes
JAK-STAT Signaling Pathway
The Janus kinase (JAK)-signal transducers and activators of transcription (STAT)
signaling pathway is widely utilized by hormone and cytokine receptors that do not have
enzymatic activity. The interaction between a ligand and receptor activates JAK.
Activated JAK binds to the receptor and phosphorylates the receptor on tyrosine
residues. The Src-homology 2 (SH2) domain within the STATs recognize and associate
with phosphorylated tyrosines within the cytosolic portion of the receptor. Next, the
STAT is phosphorylated by the active JAK. The tyrosine phosphorylation induces
dimerization of STATs and dimerized STATs translocate to the nucleus and interact
with promoters to modulate gene expression (reviewed in (83)). There are four
members of the JAK family: Jak1, Jak2, Jak3 and Tyk2, and seven members of the
STAT family: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6. However,
only STAT1, 3, 5A, 5B and 6 are expressed in mature adipocytes (reviewed in (84)).
Previous studies have shown that expression of STAT1, 5A and 5B significantly
increases during adipogenesis (85;86). STAT3, 5A and 5B have been reported to play
important roles in the adipogenic process. SiRNA-mediated knockdown of STAT3
inhibits adipocyte development (87). STAT5 proteins are also are essential for
adipogenesis. STAT5 antisense oligonucleotides inhibit growth hormone (GH)-induced
adipogenesis (88) and constitutively active STAT5 has the capability to induce
differentiation of preadipocytes (89). Ectopic expression of STAT5A not only induces
differentiation of 3T3-L1 preadipocytes (90), but also promotes adipogenesis in non-
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precursor cell lines (91). In vivo experiments have demonstrated that ectopic expression
of STAT5A can confer adipogenesis in cells that would not normally become adipocytes
(92). Also, STAT5-deficient mice have much smaller fat pads (93) and STAT5 signaling
pathways mediate the GH-induced expression of PPARγ in 3T3-L1 and C3H10T1/2
cells (94).
Previous studies have identified activators of JAK-STAT signaling pathways in
adipocytes. GH and prolactin (PRL) have been shown to activate STAT5 to modulate
gene expression (94-99). Studies from the Stephens laboratory have demonstrated that
acyl-CoA oxidase (AOX) (100) and aP2 (101) are regulated by GH, while fatty acid
synthase (FAS) (102) and pyruvate dehydrogenase kinase 4 (PDK4) (98) are
modulated by both GH and PRL. Our unpublished data also shows that the expression
of adiponectin is inhibited by GH in 3T3-L1 adipocytes, and that the STAT5 signaling
pathway mediates this response. In addition to these anterior pituitary hormones, a
variety of cytokines also utilize the JAK-STAT signaling pathway in mature adipocytes.
The pro-inflammatory cytokine IFNγ modulates expression of lipoprotein lipase (LPL)
via activation of the STAT1 signaling pathway (103). Gp130 cytokines, including
cardiotrophin-1 (104;105),

interleukin-11

(106), and leukemia inhibitory factor

(95;107;108) have been shown to utilize STAT1 and STAT3 signaling pathways in fat
cells.
NF-κB Signaling Pathway
The nuclear factor-κB (NF-κB) signaling pathway was originally identified in
immune cells, and is comprised of both positive and negative regulators. In basal
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conditions, IκB associates with NF-κB and inhibits its activity. Upon stimulation, the
interaction between ligand and receptor activates NF-κB signaling by inducing the
phosphorylation of IκB kinase (IKK). Phosphorylated IKK is able to phosphorylate IκB.
Phosphorylation results in the dissociation of IκB from NF-κB, and IκB is then
ubiquitinated and degraded. The active NF-κB translocates to the nucleus and regulates
the expression of target genes (reviewed in (109)). The five members of the NF-κB
family, p50, p52, p65 (RelA), c-Rel and RelB, share a homologous N-terminus that
contains a Rel homology domain (RHD). RHD is required for the dimerization and DNA
binding activity of NF-κB. RelB, c-Rel and p65 have their transcription activation domain
(TAD) at the C-terminus, while p50 and p52 do not have a TAD. P50 and p52 need to
associate with coactivators to induce gene expression (reviewed in (109)).
The NF-κB signaling pathway is widely used by pro-inflammatory cytokines,
including TNFα, IL-1β and LPS, which are potent inducers of insulin resistance in
adipose tissue (reviewed in (110)). NF-κB has been demonstrated to mediate TNFαinduced expression of chemokines in adipocytes (111). The increase of chemokines,
such as CCL5 (24), CXCL5 (23) and CXCL14 (25), likely contributes to the recruitment
of immune cells into adipose tissues and the impairment of insulin sensitivity. The
suppression of PPARγ expression by TNFα treatment is also mediated by activated NFκB signaling pathway (22).
ERK Signaling Pathway
Extracellular signal-regulated kinase (ERK) belongs to the family of mitogenactivated protein kinases (MAPKs). ERKs are well known for their important roles in
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regulating cell proliferation and oncogenesis. In ERKs signaling pathways, the GTPase
Ras can be activated by receptor tyrosine kinase (RTK)-Grb2-SOS axis. Activated Ras
induces the activation of Raf, which phosphorylates and activates MEK1/2. Then,
activated MEK1/2 has the capability to phosphorylate and activate ERK1/2. ERKs are
serine/threonine kinases. The activated ERKs regulate activities of important
transcription factors via phosphorylation of their seine and/or threonine residues
(reviewed in (112)). Previous studies have demonstrated that activation of the ERKs
signaling pathway induces adipogenesis through up-regulating expression of PPARγ
and C/EBPα, both of which are required for adipogenesis (113). As a universal signaling
pathway adopted by cytokines, ERKs signaling mediates many effects on gene
expression. Studies in 3T3-L1 adipocytes indicate that activation of ERKs mediates
TNFα-induced insulin resistance (114). Activation of ERKs signaling is responsible for
the TNFα-induced suppression of expression and phosphorylation of IR, IRS1, and
IRS2 (114). Studies from the Stephens laboratory have demonstrated that IFNγ-induced
ERKs activation mediates phosphorylation of PPARγ at Serine112, which facilitates the
degradation of PPARγ (54). Besides IFNγ and TNFα, other cytokines/hormones,
including GH and gp130 cytokines, have been found to activate ERKs signaling
pathway in mature adipocytes (97;115).
1.4 Lipocalin-2
Lipocalin-2 (LCN2) belongs to the lipocalin family, a group of proteins that
transport small and hydrophobic molecules in circulation (116). LCN2 was first identified
for its interaction with matrix metalloproteinase 9 (MMP-9). LCN2 is able to stabilize
MMP-9 and protect it from degradation (117). Follow-up studies indicate that LCN2
12

plays important roles in the innate immune response by limiting bacterial growth
(118;119). More functional studies have revealed that LCN2 has the ability to promote
migration of vascular smooth muscle cells (120) and induce epithelial-mesenchymal
transition (121). A recent study also demonstrates that LCN2 is increased in chronic
kidney diseases and may participate in pathogenic processes (122). Studies in the
central nervous system have shown that LCN2 expression is elevated by viral infection
(123). It is likely that LCN2 has a variety of different functions in different tissues.
Previous research has shown that LCN2 can be produced and secreted from
mature adipocytes (124). LCN2 expression significantly increases during adipogenesis
(125). Animal studies have reported that LCN2 expression is substantially induced in
ob/ob and db/db mice (125). In human studies, circulating LCN2 is positively related
with adiposity, blood triglyceride, blood glucose and insulin resistance (126;127), and
negatively associated with high-density lipoprotein cholesterol (127). Previous studies
have shown that some inducers of insulin resistance, IL-1β (128), lipopolysaccharide
(LPS) (129) and glucocorticoids (130) can up-regulate LCN2 expression. Also, the
insulin sensitizer thiazolidinedione inhibits LCN2 expression.
Although it has been demonstrated that LCN2 expression is increased in obesity
and insulin resistance (125), the mechanisms involved in this process and the functions
of LCN2 in insulin resistance are unclear. LCN2 administration to 3T3-L1 adipocytes
has been shown to increase the expression of PPARγ and adiponectin and attenuate
the inhibitory effect of TNFα on insulin-stimulated glucose uptake (131). However,
another study showed that shRNA-mediated knockdown of LCN2 improves insulin
sensitivity and insulin-stimulated glucose uptake in adipocytes (125). To clarify the roles
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of LCN2 in the pathogenesis of insulin resistance, LCN2 knockout mice were created.
However, the LCN2 null mice created and studied by different groups showed
completely different phenotypes. Study from Chen’s lab reported that LCN2 deficiency
results in the impairment of insulin sensitivity (132), while another group found that
LCN2-deficient mice are protected from obesity-related insulin resistance (133). Later, a
third paper published by Rosen’s lab showed that LCN2 knockout does not substantially
affect obesity-induced insulin resistance (134). Although the functions of LCN2 in
modulating insulin sensitivity are still unknown, all the studies provide evidence that
LCN2 is induced in adipose tissue in conditions of insulin resistance. There is also
evidence that LCN2 deficiency enhances the HFD-induced expansion of inguinal fat
(135), and LCN2 administration increases energy expenditure in vivo and up-regulates
expression of genes participating in β-oxidation to increase fatty acid oxidation in
adipocytes (136).
1.5 Research Focus
Obesity and obesity-related metabolic diseases are a worldwide epidemic and
health risk. Adipocyte and adipose tissue play essential roles in the pathogenic
processes associated with metabolic disease states. In our studies, we examined LCN2
expression in adipocytes in vitro and in vivo. These results reveal the mechanisms
involved in the regulation of LCN2 in obesity and insulin resistance. The results
demonstrated that IFNγ and TNFα, the two major pro-inflammatory cytokines, induce
LCN2 expression and secretion both in vitro and in vivo. These studies suggest that
pro-inflammatory cytokines from immune cells in adipose tissue affect the endocrine
functions of adipocytes in obese and insulin resistant conditions. Studying the signaling
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pathways utilized by the pro-inflammatory cytokines has also revealed how adipocyte
function is influenced by chronic inflammation. In our studies, we demonstrate that the
induction effects of IFNγ are mediated by STAT1 and ERKs signaling pathways and the
TNFα effects are mediated via NF-κB and ERKs signaling pathways in mature
adipocytes. Moreover, our novel results have revealed that ERKs signaling pathways
interact with STAT1 and NF-κB pathways via modulation of STAT1 and p65 serine
phosphorylation. In silico, in vitro, and in vivo studies of the murine and human LCN2
promoters have identified conserved transcription factor binding sites. These studies
have revealed the mechanisms involved in LCN2 expression in obesity and insulin
resistance and have increased our knowledge of signaling pathways utilized by proinflammatory cytokines in adipocytes.
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CHAPTER 2. STAT1, NF-κB AND ERKS PLAY A ROLE IN THE INDUCTION OF
LIPOCALIN-2 EXPRESSION IN ADIPOCYTES

2.1 Introduction
Adipose tissue is a major insulin sensitive tissue that plays key roles in regulating
energy metabolism and insulin sensitivity (3;137;138). Chronic inflammation and
infiltration of immune cells in adipose tissues has been demonstrated to modulate
adipocyte function and result in alterations of hormone secretion and insulin sensitivity
(1;16). TNFα and IFNγ are important pro-inflammatory cytokines that are known to be
secreted from immune cells that infiltrate into adipose tissues (1;44;139). These
immune cells have the ability to induce insulin resistance in both cultured adipocytes
and experimental animal models (35;44;140;141). IFNγ signals via activating Janus
kinase (JAK)-signal transducer and activator of transcription 1 (STAT1) signaling
pathway and extracellular signal-regulated kinases (ERKs) mediated signaling pathway
(141;142). TNFα utilizes various signaling pathways and can stimulate both nuclear
factor kappa B (NF-κB) signaling pathway and ERKs mediated signaling pathway
(143;144).

This chapter, STAT1, NF-κB AND ERKS PLAY A ROLE IN THE INDUCTION OF LIPOCALIN-2
EXPRESSION IN ADIPOCYTES, previously appeared as Zhao P & Stephens JM, STAT1, NF-κB and
ERKs play a role in the induction of lipocalin-2 expression in adipocytes, Mol Metab. 2013. It is reprinted
by permission of Elsevier.
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Lipocalins are a family of proteins that bind and transport small or hydrophobic
molecules with conserved ligand binding sites (116). As a member of the lipocalin family,
lipocalin-2 (LCN2), also called neutrophil gelatinase-associated lipocalin (NGAL), was
initially discovered as a matrix metalloproteinase 9 (MMP-9) binding protein that
attenuated MMP-9 degradation (117). Studies have shown that LCN2 increases during
exposure to invading bacteria (145) and can be bound to bacterial siderophores to limit
bacterial growth by reducing iron uptake (118;119). More recent research has revealed
that LCN2 is secreted from mature adipocytes (124). Expression of LCN2 is significantly
up-regulated in conditions of insulin resistance and type 2 diabetes (T2DM) (125).
Human studies indicate that circulating LCN2 positively correlates with adiposity,
triglyceride, blood glucose level, insulin resistance, and is negatively related to highdensity lipoprotein cholesterol (126;127). However, the roles of LCN2 in the pathology
of adipose tissue insulin resistance are still unclear. There is evidence that LCN2 can
induce the expression of PPARγ and adiponectin (131) and that administration of LCN2
attenuates the inhibitory effect of TNFα on insulin-stimulated glucose uptake (131).
However, other data indicates that knockdown of LCN2 improves insulin action in
adipocytes (125). In order to clarify the functions of LCN2 in whole body insulin
sensitivity, LCN2 knockout mice have been generated by several labs. However, the
results of these studies have further clouded our understanding of the functions of LCN2
and the topic is even more controversial. In one study, global LCN2 deficiency caused
dyslipidemia, fatty liver and insulin resistance (132). On the contrary, a separate study
indicated that LCN2 null mice had improved aging and obesity-mediated insulin
resistance (133), supporting the notion that the lack of LCN2 is metabolically favorable.
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The most recent characterization of LCN2 deficient mice indicates that LCN2 deficiency
did not have a significant effect on age or obesity-induced insulin resistance (134).
Collectively, these studies suggest that the roles of LCN2 in modulating insulin
sensitivity are still unclear. Nonetheless, there are numerous studies and clear and
convincing evidence to demonstrate that modulation of LCN2 in mice and humans
significantly affects insulin sensitivity. Our studies have focused on understanding the
regulation of LCN2 expression by factors that contribute to the pathogenesis of insulin
resistance.
To enhance our understanding of LCN2 in obesity and insulin resistance, we
performed mechanistic studies to examine how LCN2 expression is induced in
adipocytes. Our results demonstrate that the increase of LCN2 expression is mediated
by pro-inflammatory cytokines that are present in adipose tissue in conditions of insulin
resistance in mice and man. We observed that LCN2 expression and secretion was
induced by IFNγ and TNFα in both murine 3T3-L1 adipocytes and human subcutaneous
adipocytes. STAT1 and ERKs 1 and 2 signaling pathways mediated the effects induced
by IFNγ and the effects of TNFα on LCN2 expression were mediated by both NF-κB and
ERKs 1 and 2 signaling pathways. Our studies of the murine LCN2 promoter identified
five STAT1 binding sites and one NF-κB binding site. Inhibition of ERKs signaling
pathway attenuated the stimulatory effects of both IFNγ and TNFα on LCN2 expression.
Inhibition of ERKs 1 and 2 reduced the activity of STAT1 and NF-κB without having any
significant effects on the nuclear localization or DNA binding activity of these proinflammatory transcription factors. These mechanistic studies provide insight into the
modulation of LCN2 that occurs during insulin resistance.
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2.2 Experimental Procedures
Cell culture
Murine 3T3-L1 preadipocytes were grown to 2 days after confluence in
Dulbecco's Modified Eagle's Media (DMEM) with 10% bovine serum. Media was
changed every 48 h. 0.5 mmol/l 3-isobutyl-methylxanthine, 1 μmol/l dexamethasone,
and 1.7 μmol/l insulin (MDI) cocktail were used to induce preadipocytes differentiation in
DMEM containing 10% fetal bovine serum (FBS). After 48 h, the media was replaced by
DMEM with 10% FBS. For serum deprivation, media was change to DMEM containing
0.3% BSA for 16–20 h before treatment. DMEM was purchased from Sigma. Bovine
and FBS were purchased from Hyclone. Human subcutaneous adipocytes in 12-well
plates were purchased from Zen-Bio. Cells were serum-deprived for 16 h before
treatment. Recombinant mouse and human IFNγ were purchased from R&D Systems.
Recombinant mouse and human TNFα were purchased from Gibco. Actinomycin D was
purchased from Sigma.
Preparation of whole cell extracts
Cell monolayers were harvested in a non-denaturing IP buffer that contained
10 mmol/l Tris (pH 7.4), 150 mmol/l NaCl, 1 mmol/l EGTA, 1 mmol/l EDTA, 1% Triton X100, 0.5% Nonidet P-40, with protease inhibitors 1 μmol/l phenylmethylsulfonyl fluoride,
1 μmol/l pepstatin, 50 mU trypsin inhibitory aprotinin, 10 μmol/l leupeptin, and
phosphatase inhibitor 2 mmol/l sodium vanadate. The cells were scraped off the plates
and the extract was passed through a 20 g needle three times. The extract was
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centrifuged at 9500gfor 10 min at 4 °C. Supernatants were collected and analyzed with
BCA (Pierce) to quantify protein content of whole cell extract.
RNA analysis
Total RNA was isolated from cell monolayers with RNeasy mini kit (Qiagen).
10 μl of RNA extract was used for reverse transcription PCR. cDNA was analyzed by
delta delta ct real-time PCR with SYBR supermix reagent (Takara) and Applied
Biosystem 7900HT system. Cyclophilin A was used as endogenous control. Following
primers were used for the real-time PCR: mLCN2 forward TGCAAGTGGCCAC
CACGGAG and reverse GCATTGGTCGGTGGGGACAGAGA; mCyclophilin A forward
CCACTGTCGCTTTTCGCCGC and reverse TGCAAACAGCTCGAAGGAGACGC.
3T3-L1 adipocyte fractionation
Cell monolayers were harvested in nuclear homogenization buffer containing
20 mmol/l Tris (pH 7.4), 10 mmol/l NaCl, 3 mmol/l MgCl2, 1 μmol/l dithiothreitol, with
protease inhibitors listed above and 2 mmol/l sodium vanadate. Nonidet P-40 was
added to final concentration of 0.15%. Cells were homogenized with 18 strokes in a
Dounce homogenizer and centrifuged at 500g for 5 min. Supernatants were transferred
to another tube as cytosolic extract. The precipitated nuclear pellets were resuspended
in one-half volume of nuclear homogenization buffer and were centrifuged as before.
The supernatant was removed and discarded. The majority of the pellet (intact nuclei)
was resuspended in nuclear extraction buffer containing 20 mmol/l HEPES (pH 7.9),
150 mmol/l NaCl or 420 mmol/l NaCl, 1.5 mmol/l MgCl2, 0.2 mmol/l EDTA, 1 μmol/l
dithiothreitol, 25% glycerol and the with protease inhibitors listed above with 2 mmol/l
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sodium vanadate. Resuspended nuclei were passed three times through a 20G needle
every 10 min and extracted for 30 min on ice. The samples were centrifuged at 9500g at
4 °C for 10 min. The resulting supernatant was a nuclear extract.
Gel electrophoresis and immunoblotting
Proteins were separated in 7.5% or 10% polyacrylamide gels containing SDS,
and transferred to nitrocellulose membrane (Bio-Rad) in 25 mmol/l Tris, 192 mmol/l
glycine, and 20% methanol. After transfer, the membrane was blocked in 4% milk for
1 h at room temperature, and incubated with primary antibody overnight at 4 °C. Results
were visualized with horseradish peroxidase-conjugated secondary antibodies (Jackson
ImmunoResearch Laboratory) and enhanced chemiluminescence (Pierce). STAT1
antibody was purchased from Cell Signaling Technology. LCN2 antibody was from R&D
System. STAT5A, p65, ERK1/2 antibodies were from Santa Cruz technology.
Adiponectin antibody was from Thermo-Pierce. STAT1pY antibody was from Millipore.
Active ERK1/2 antibody was from Promega.
Electrophoretic mobility shift analysis
Double-stranded oligonucleotides were annealed by heating single-stranded
oligonucleotides (sequences shown in Table 1 and Table 2) in 95 °C water bath and
gradually cooling to room temperature. 4 μg double-stranded oligonucleotides were
labeled with 20 μCi [α-P32]dCTP (PerkinElmer) and 1 μl of each 5 mM dATP, dTTP,
dGTP using Klenow fragment. The mix was incubated for 15 min at 30 °C. The reaction
was stopped by adding 1 μl of 0.5 M EDTA. Labeled double-stranded oligonucleotides
were purified with illustra MicroSpin G-25 Columns (GE Healthcare) according to
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manufacturer's instructions. Radioactivity of labeled oligonucleotides was determined by
scintillation counting. Nuclear extracts were incubated with the labeled oligonucleotides
for 30 min on ice. The samples were separated in a pre-run (30 min, 200 V at 4 °C) 6%
acrylamide/bisacrylamide TBE gel. Nuclear extracts were pre-incubated with 1 μg
antibody (STAT1, STAT3, STAT5A, STAT5B or p65 from Santa Cruz Technology) for
1 h at room temperature for supershift assay. The gels were run at 200 V for ~3.5 h,
dried at 80 °C for 45 min with vacuum, and then exposed to Eastman Kodak Co.
BioMax MS film with a Kodak BioMax high energy intensifying screen.
Table 1. Oligos for EMSA
EMSA oligos
GTATTTCAACAGAAT
-160

GCCCTGGGAATGTCCCT
-266

GTACATTCTGTTGAAAT
GACACTTCCAGGATA

-619

GTCTGTTCCTGTAAATG
-676

GATTATCCTGGAAG

TGCCATTTACAGGAAC

GTGAGTCCCTGAGAGT
-705

GGAGAGGGTGAGTCCCT
-713

GAACTCTCAGGGACT
CCCACTTTCCCCAAGGGC

-1014

GGAGCCCTTGGGGAAAG

GCACATGGGAGACCCCAA
GGATCCTTGAGATGC

-3132

AGTACAAAGAAACA
AGAGTTTCTGGATC

-3159

CTCAGGGACTCACCCT
GAACTTGGGGTCTCCCA

-1795

GGTTGTTTCTTTGTA
-1822

TAGAGGGACATTCCCA

GTTGCATCTCAAGGAT
CCAGTTTCTGGAAGAG

-3171

TCGGATCCAGAAAC
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GAAACTCTTCCAGAAA

Table 2. Mutant oligos for EMSA
Mutant EMSA oligos
GCCCTGAGAATGTACCT
-266

GACACCTCCAGGCTA
-619

TAGAGGTACATTCTCA
GTCTGTACCTGTCAATG

GGTTGTCTCTTTGTC

-676

-1822
TGCCATTGACAGGTAC

-3171

GATTAGCCTGGAGG

AGGACAAAGAGACA

CCAGTCTCTGGACGAG
GAAACTCGTCCAGAGA

Chromatin immunoprecipitation
ChIP assay was performed with SimpleChIP® Enzymatic Chromatin IP Kit (Cell
Signaling Technology) according to the protocol supplied by company. Cells were
serum deprived overnight in DMEM containing 0.3% bovine serum. Cells were treated
with IFNγ or TNFα for 30 min in the presence or absence of UO129, an ERK inhibitor
(Promega). Adipocytes were cross-linked with formaldehyde and glycine. Chromatin
extracts were prepared after sonication of harvested cells. Immunoprecipitation was
performed with specific STAT1 (Cell Signaling Technology) or p65 (Cell Signaling
Technology) antibodies. Rabbit normal IgG was used as a negative control. Purified
DNA was quantified by real-time PCR with following primers: -266 forward
GTGGACAGGCAGTCCAGATCTGAG and reverse AAGATTTCTGTCCCTCTCTCCC
CC; -619 forward CTGTTCCTGTAAATGGCAGTGGGG and reverse GGGTGAGCAAG
CTGAGAGTGAATG; -676 forward TAAGGACTACGTGGCACAGGAGAG and reverse
GAAGTGTCCAATACCTTGAGCCCC; -1014 forward GCTTCTGCCCAAAGTAACTGG
AGT and reverse TAAGGACTGCAACCTCGGTGTCAT; -1822 forward CTGCCC
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TGAGTGTTGGGTTCAAAG and reverse CTGGGGATGTAGCTCTCTGGTGTT; -3171
forward TAGTCCTGCATTCAGTTTGCAGGC and reverse ACCCAGGTCCAATCCA
CATGAAGA. 500 nM of each primer and 2 μl ChIP product were used with SYBR green
supermix and ROX buffer (Takara) in 20 μl PCR reaction. Percentage of input was
calculated by the formula:
Percentage of input=2%×2(C[T] 2% input sample−C[T] IP sample).
Plasmid constructs
A 3470 bp-fragment of LCN2 promoter (−3358 to 112) was cloned from genomic
DNA of mouse liver. The fragment was amplified with following primers: forward:
GATCGGTACCAAAGGGCTCTCCAGGTTCTC;

reverse:

GATCGATATCGGCAGGG

ATCAAGTTCTGAG. Nucleotides were added to the 5′ ends of each primer so that the
forward primer could be digested by KpnI and the reverse primer by EcoRV for ligation
into the pGL4.27 vector to create pGL4.27-LCN2pro. Plasmids were sequenced for
verification of nucleotide sequence.
Plasmid transfection and luciferase reporter assays
Mature 3T3-L1 adipocytes in six-well plates were transfected with 2 μg pGL4.27LCN2pro by using Dharmacon turboFect reagent (ThermoScientific). 2 μg pRLTK/renilla vector was co-transfected to control transfection efficiency. After 24 h, the
adipocytes were pretreated with UO126 for 30 min and that was followed by IFNγ or
TNFα treatment for 24 h. Cell lysis was prepared with passive lysis buffer. Luciferase
activity was measured with the Dual Luciferase Reporter System (Promega). Relative
luciferase units were calculated by dividing firefly luciferase activity values by renilla
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luciferase activity. Each condition was performed in triplicate and on three independent
batches of adipocytes.
2.3 Results
LCN2 expression and secretion is up-regulated by pro-inflammatory cytokines
Previous studies showed that LCN2 is expressed in adipocytes and increased in
obese and diabetic subjects (125). However, the mechanisms involved in the induction
of LCN2 expression are unknown. In our studies, we observed that both IFNγ and TNFα
induced the expression and secretion of LCN2. Whole cell extracts and media samples
were prepared from 3T3-L1 adipocytes that were untreated or treated for 24, 48, or 72
hours. As shown in Figures 2.1 and 2.2, LCN2 expression and secretion were induced
by IFNγ and TNFα treatment within 24h. After 24h IFNγ treatment, the cellular levels of
LCN2 were induced and remained high. However, the effect of TNFα on LCN2 levels
increased over time. Since adiponectin expression and secretion is attenuated by both
IFNγ and TNFα (19;21), we used it as control to assess the effectiveness of cytokine
treatment. STAT5A was used as a loading control. As expected, cytokine treatment
decreased adiponectin levels, but did not effect STAT5A expression. To determine if the
observed effects were dependent on new transcription, we pretreated 3T3-L1
adipocytes with Actinomycin D for 30 min, followed by a IFNγ or TNFα treatment. As
shown in Figure 2.3, TNFα is a more potent inducer of LCN2 mRNA than IFNγ. In
addition, the presence of Actinomycin D inhibited the ability of both inflammatory
mediators to induce LCN2 mRNA expression.
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Figure 2.1. IFNγ and TNFα induce LCN2 expression and secretion in 3T3-L1 adipocytes.
Mature 3T3-L1 adipocytes were chronically treated with 100ng/ml IFNγ. Media was
collected and whole cell extract was harvested at indicated time. Time 0 indicates no
treatment. 250μg protein from media samples and 150μg of whole cell extracts were
subjected to western blot analysis.

Figure 2.2. IFNγ and TNFα induce LCN2 expression and secretion in 3T3-L1 adipocytes.
Mature 3T3-L1 adipocytes were chronically treated with 0.5nM TNFα. Media was
collected and whole cell extract was harvested at indicated time. Time 0 indicates no
treatment. 250μg protein from media samples and 150μg of whole cell extracts were
subjected to western blot analysis.
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Figure 2.3. IFNγ and TNFα induce LCN2 expression and secretion in 3T3-L1 adipocytes.
Adipocytes were pretreated with 5μg/ml Actinomycin D for 30min, and then treated with
IFNγ or TNFα for 16h. Total RNA was isolated and analyzed with reverse transcription
and qPCR. Cyclophilin A was used as an endogenous control.

The effects of IFNγ and TNFα on LCN2 expression are additive
Next, we evaluated whether IFNγ and TNFα induced LCN2 expression by
activating the same or different signaling pathways in adipocytes. Mature 3T3-L1
adipocytes were treated for 16 hours and total RNA was isolated and analyzed by
quantitative real-time PCR. As shown in Figure 2.4, TNFα is a more potent inducer of
LCN2 mRNA than IFNγ. However, the presence of both IFNγ and TNFα always resulted
in at least an additive effect on LCN2 expression. This additive effect is also observed
with LCN2 protein expression and secretion (Figure 2.5). Collectively, these data
indicate that IFNγ and TNFα affected LCN2 expression via stimulating different
signaling pathways.
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Figure 2.4. The effects of IFNγ and TNFα on LCN2 expression are additive. Mature
3T3-L1 adipocytes were treated with 100ng/ml IFNγ or 0.5nM TNFα or both cytokines.
RNA was isolated 16h later and subject to reverse transcription and qPCR.

Figure 2.5. The effects of IFNγ and TNFα on LCN2 expression are additive. Whole cell
extracts and media samples were collected after a 24h treatment. 250µg of protein from
media samples and 150µg of whole cell extracts were analyzed by western blot analysis.

28

Identification of NF-κB and STAT1 binding sites in LCN2 promoter
Since the induction of LCN2 expression by IFNγ or TNFα appeared to be
mediated by different signaling pathways, we examined several signaling pathways
known to mediate the effects of IFNγ and TNFα. We examined the role of STAT1, NFκB and ERK1/2 signaling pathways in the ability of IFNγ and TNFα to induce LCN2
expression. First, we performed an analysis to search for potential STAT1 and NF-κB
sites in the promoter of the murine LCN2 gene. Three potential NF-κB binding sites
(Table 3) and nine potential STAT1 binding sites (Table 5) were identified by sequence
analysis and experimentally examined by performing both electrophoretic mobility shift
assays (EMSA) and chromatin immunoprecipitation (ChIP). Only one of the potential
NF-κB binding sites was confirmed to interact with nuclear extracts from TNFα treated
adipocytes and binding specificity was assessed by performing cold competition and
generating a mutated binding site (Figure 2.6 and Table 4). An increase of cold
competitor reduced the interaction between radioactively labeled probe and nuclear
protein. A mutated probe (Table 4) did not associate with nuclear protein. A specific p65
antibody was used to perform supershift analysis to determine whether NF-κB
comprised the DNA binding complex. As indicated in Figure 2.7, pre-incubation with a
p65 antibody resulted in a supershift of the TNFα induced binding, which suggests that
the p65 component of NF-κB is present in the DNA-protein complex. Chromatin
immunoprecipitation (ChIP) was also performed to examine the association of p65 with
the murine LCN2 promoter. As shown in Figure 2.8, p65 bound to the murine LCN2
promoter in vivo.
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Table 3. NF-κB binding sites in LCN2 promoter
Gene
Consensus
LCN2
LCN2
LCN2

Position

Sequence

-266 to -247
-713 to -694
-1795 to -1774

GGG NNN NNC C
GC CCT GGG AAT GTC CCT CTG
GG AGA GGG TGA GTC CCT GAG
GAA CTT GGG GTC TCC CAT GTG C

TNFα responsive
EMSA
ChIP
Yes
No
No

Yes
No
No

Table 4. Mutated NF-κB binding sites
Gene

Position

Mutated sequence

TNFα responsive
(EMSA)

LCN2

-266 to -247

GC CCT GAG AAT GTA CCT CTG

No

Figure 2.6. TNFα induces NF-κB binding to LCN2 promoter. Mature 3T3-L1 adipocytes
were treated with 0.5 nM TNFα for 20min. Cytosolic and nuclear extracts were
separated from treated or untreated mature adipocytes. 10μg of each extract was
incubated with 50,000cpm/μl 32P-labeled double-stranded oligonucleotides of murine
LCN2 promoter. Protein-DNA complexes were resolved by EMSA. Free probe was run
out of the gel. The TNFα-responsive shift is indicated with an arrow (left panel). For cold
competition, nuclear extracts were incubated with 50,000cpm/μl 32P-labeled probe and
2μl unlabeled oligonucleotides of different concentrations (0.4μmol/L, 2μmol/L,
10μmol/L) (middle panel). Nuclear extracts were also incubated with 50,000cpm/μl 32Plabeled double-stranded probe of LCN2 promoter or probe of mutated sequence (right
panel).
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Figure 2.7. TNFα induces NF-κB binding to LCN2 promoter. Cytosolic and nuclear
extracts were prepared from mature adipocytes treated with TNFα for 20min. For
supershift assay, the nuclear protein was pre-incubated with 1μg indicated antibody for
1h, and then incubated with 32P-labeled probe and protein-DNA complexes were
resolved by EMSA.

Figure 2.8. TNFα induces NF-κB binding to LCN2 promoter. 3T3-L1 adipocytes were
treated or untreated with 0.5nM TNFα for 30min, and then cross-linked with
formaldehyde. Chromatin extracts were prepared and subject to immunoprecipitation
with IgG (Negative control) or p65 antibody. IP products were analyzed by qPCR.
Percentage of input was calculated and normalized to negative control. ***, P<0.01.

31

Nine potential STAT1 binding sites (Table 5) were experimentally examined by
performing both EMSA and ChIP. EMSA analysis revealed that four of these sites
interacted with nuclear protein from IFNγ treated adipocytes (Figure 2.9). Specificity
was assessed by performing cold competition and generating mutated binding sites
(data not shown) (Table 6). Supershift assay was performed with specific STATs
antibodies to demonstrate whether these proteins were involved in the DNA binding
complex. STAT1 was shown to bind to all four binding sites. To our surprise, STAT5A
and STAT5B also interacted with -619, -1822 and -3171 binding sites (Figure 2.10).
Since growth hormone (GH) is a physiological activator of STAT5A and STAT5B (99),
we examined the ability of GH to regulate binding to these STAT sites. However, there
was no association detected between labeled oligonucleotides and nuclear protein from
GH treated adipocytes (data not shown). When we performed ChIP analysis to test
these STAT binding sites, we confirmed the four binding sites that were validated by
EMSA and observed STAT1 binding at one additional site (Table 5). Of note, this
binding site at -1014 was not positive with nuclear protein in vitro, but was verified by
ChIP using a STAT1 antibody (Figure 2.11). For all the five STAT1 binding sites, we did
not observe any IFNγ induced interaction with STAT5 in vivo (data not shown).
ERKs signaling modulates the ability of TNFα and IFNγ to induce LCN2 expression
without having significant effects on STAT1 and NF-κB nuclear translocation or DNA
binding activity
Besides activating transcription factors like STAT1 and NF-κB, both IFNγ and
TNFα acutely activate ERKs 1 and 2 (Figure 2.12). Mature adipocytes were pre-treated
with UO126, a specific ERK inhibitor for 30 min and then nuclear translocation and
tyrosine phosphorylation of STAT1 was examined after an IFNγ or TNFα treatment for
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Table 5. STAT1 binding sites in LCN2 promoter
Gene

Position

Sequence

Consensus

IFNγ responsive
EMSA
ChIP

TTC N2-4 GAA

LCN2

-160 to -142

G TAT TTC AAC AGA ATG TAC

No

No

LCN2

-619 to -602

GA CAC TTC CAG GAT AAT C

Yes

Yes

LCN2

-676 to -657

GT CTG TTC CTG TAA ATG GCA

Yes

Yes

LCN2

-705 to -688

GT GAG TCC CTG AGA GTT C

No

No

LCN2

-1014 to -994

CCC ACT TTC CCC AAG GGC TCC

No

Yes

LCN2

-1822 to -1806

GGT TGT TTC TTT GTA CT

Yes

Yes

LCN2

-3132 to -3115

GGA TCC TTG AGA TGC AAC

No

No

LCN2

-3159 to -3143

AG AGT TTC TGG ATC CGA

No

No

LCN2

-3171 to -3152

CC AGT TTC TGG AAG AGT TTC

Yes

Yes

Table 6. Mutated STAT1 binding sites
Gene

Position

Mutated sequence

IFNγ responsive
(EMSA)

LCN2

-619 to -602

GA CAC CTC CAG GCT AAT C

No

LCN2

-676 to -657

GT CTG TAC CTG TCA ATG GCA

No

LCN2

-1822 to -1806

GGT TGT CTC TTT GTC CT

No

LCn2

-3171 to -3152

CC AGT CTC TGG ACG AGT TTC

No

20 minutes. As shown in Figure 2.12, the IFNγ induced nuclear translocation and
tyrosine phosphorylation of STAT1 was unaffected by ERKs inhibition. TNFα induced
the nuclear translocation of p65 that was also unaffected by ERKs inhibition. The
efficacy of ERKs inhibition is shown by using a phospho-specific antibody to assess
ERKs activation. Also, note that IFNγ induced a modest increase in the nuclear content
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Figure 2.9. IFNγ induces STAT1 binding to LCN2 promoter. Mature 3T3-L1 adipocytes
were treated with 100ng/ml IFNγ for 20 min for the preparation of cytosolic and nuclear
extracts. There was no binding in any cytosolic extracts (data not shown). 10μg of
nuclear extract was incubated with 50,000cpm/μl 32P-labeled double-stranded
oligonucleotides of murine LCN2 promoter. The protein-DNA complexes were resolved
by EMSA. Free probe was run out of the gel. The IFNγ responsive shift is indicated with
an arrow.

Figure 2.10. IFNγ induces STAT1 binding to LCN2 promoter. Nuclear extracts were
prepared from mature adipocytes treated with IFNγ for 20 min. For super shift assay,
the nuclear protein was pre-incubated with 1μg indicated antibody for 1h, and then
incubated with 32P-labeled probe. Protein-DNA complexes were resolved by EMSA.
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Figure 2.11. IFNγ induces STAT1 binding to LCN2 promoter. 3T3-L1 adipocytes were
treated or untreated with 100ng/ml IFNγ for 30min, and then cross-linked with
formaldehyde. Chromatin extracts were prepared and subject to immunoprecipitation
with IgG (Negative control) or the STAT1 antibodies indicated in the figure. IP products
were analyzed by qPCR. Percentage of input was calculated and normalized to
negative control. ***, P<0.01.

of STAT5A. Although, ERKs inhibition did not affect the ability of these pro-inflammatory
cytokine to induce nuclear translocation of STAT1 and p65, it did have substantial
effects on the ability of these cytokines to induce LCN2 expression. As shown in Figure
2.13, the induction of LCN2 mRNA levels by IFNγ and TNFα was repressed by ERKs
inhibition. However, EMSA analysis revealed no alterations in binding to the NF-κB site
in the LCN2 promoter in vitro (Figure 2.14) and ChIP analysis suggested that NF-κB
binding to this site was not significantly altered in vivo (P=0.0538) (Figure 2.15). We
also examined the STAT1 binding to the LCN2 promoter under conditions where ERKs
were inhibited. As shown in Figure 2.16 and 2.17, there was no difference in binding in
vitro or in vivo for any of the STAT1 binding sites identified. To determine if ERKs
inhibition modulated LCN2 promoter activity in adipocytes, we cloned ~3.5 kb of the
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murine LCN2 promoter into a pGL4.27 vector expressing firefly luciferase. This vector
was transiently transfected into 3T3-L1 adipocytes. A Renilla-TK vector was cotransfected to control for transfection efficiency. One day after transfection, the cells
were treated with IFNγ or TNFα for 24h in the presence or absence of the ERK inhibitor.
A dual-luciferase reporter assay was performed to quantitate the expression of
luciferase. The results clearly showed that the ~3.5 kb segment, immediately upstream
of the transcription start site within the LCN2 promoter was sensitive to both proinflammatory cytokines. The promoter activity was highly similar to what we observed
for the induction of LCN2 mRNA (refer to Figures 2.4 and 2.13). However, UO126
pretreatment abrogated the stimulation of luciferase expression by both IFNγ and TNFα
indicating that the inhibition of ERKs impaired the transcription activation activity of
STAT1 and NF-κB (Figure 2.18).

Figure 2.12. ERK inhibition attenuates the ability of IFNγ and TNFα to induce LCN2
without modulating the nuclear translocation or DNA binding activity of STAT1 and NFκB. Cytosolic and nuclear extracts were prepared from mature 3T3-L1 adipocytes
treated or untreated with IFNγ or TNFα for 20min in the presence or absence of 50μM
UO126. 100μg protein of each sample was subject to Western blot analysis.
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Figure 2.13. ERKs inhibition attenuates the ability of IFNγ and TNFα to induce LCN2
without modulating the nuclear translocation or DNA binding activity of STAT1 and NFκB. Mature 3T3-L1 adipocytes were pretreated with 50μM UO126 for 30min, and then
treated with IFNγ or TNFα for 16h. Total RNA was isolated and analyzed with reverse
transcription and qPCR. Cyclophilin A was used as endogenous control. ***, P<0.01.

Figure 2.14. ERKs inhibition attenuates the ability of IFNγ and TNFα to induce LCN2
without modulating the nuclear translocation or DNA binding activity of STAT1 and NFκB. Nuclear extracts were separated from adipocytes untreated or treated with TNFα for
20 min in the presence or absence of UO126. 10μg of nuclear extract was incubated
with 50,000cpm/μl 32P-labeled double-stranded oligonucleotides of murine LCN2
promoter. Protein-DNA complexes were resolved by EMSA.
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Figure 2.15. ERKs inhibition attenuates the ability of IFNγ and TNFα to induce LCN2
without modulating the nuclear translocation or DNA binding activity of STAT1 and NFκB. 3T3-L1 adipocytes were untreated or exposed to TNFα for 30 min in the presence
or absence of UO126, and then cross-linked with formaldehyde. Chromatin extracts
were prepared and subject to immunoprecipitation with IgG (Negative control) or p65
antibody. IP products were analyzed by qPCR. Percentage of input was calculated and
normalized to negative control. ***, P<0.01.

Figure 2.16. ERKs inhibition attenuates the ability of IFNγ and TNFα to induce LCN2
without modulating the nuclear translocation or DNA binding activity of STAT1 and NFκB. Nuclear extracts were separated from untreated adipocytes or treated with IFNγ for
20 min in the presence or absence of UO126. Protein-DNA complexes were resolved by
EMSA as described above.
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Figure 2.17. ERKs inhibition attenuates the ability of IFNγ and TNFα to induce LCN2
without modulating the nuclear translocation or DNA binding activity of STAT1 and NFκB. 3T3-L1 adipocytes were untreated or exposed to IFNγ for 30min (-/+) UO126, and
then cross-linked with formaldehyde. Chromatin IP experiments were performed with
STAT 1 antibody for each of the LCN2 promoter sites indicated. ***, P<0.01.

Figure 2.18. ERKs inhibition impairs the induction of LCN2 promoter by both IFNγ and
TNFα in adipocytes. Mature 3T3-L1 adipocytes were transiently transfected with murine
LCN2 promoter (-3358 to 112)/luciferase plasmid. A TK/renilla vector was used as
control for transfection efficiency. After 24h post transfection, adipocytes were
pretreated with 50 μM UO126 for 30 min and then stimulated with IFNγ or TNFα for 24 h.
Relative light units (RLU) were calculated by dividing firefly luciferase activity by renilla
luciferase activity. ***, P<0.01.
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IFNγ and TNFα induce LCN2 expression in human subcutaneous adipocytes
An in silico analysis of the human LCN2 promoter revealed five potential STAT1
binding sites at −856, −885, −1405, −1934, and −3610. As shown in Table 7,
sequences of all these potential binding sites are largely conserved between mice and
humans. Furthermore, the distribution of these sites in the human promoter is
comparable with the STAT1 binding sites we characterized in the murine LCN2
promoter. We also identified one potential NF-κB binding site in the human LCN2
promoter at -176 and this is completely conserved between humans and mice (Table 7).
Our in silico analysis of the human LCN2 promoter strongly suggests that STAT1 and
NF-κB also mediate the induction of LCN2 expression in human adipocytes. In order to
determine if the regulation we observed in murine 3T3-L1 adipocytes also occurred in
human cells, we purchased human adipocytes. Human IFNγ and TNFα were used to
treat human subcutaneous adipocytes for 24 h. As shown in Figure 2.19, the expression
of LCN2 was up-regulated by both IFNγ and TNFα in human adipocytes.
2.4 Discussions
The endocrine properties of adipocytes are one of their most critical functions
(138). Leptin and adiponectin are two hormones that are produced exclusively from
adipocytes in mouse and man. Like LCN2, these hormones are also implicated in
modulating insulin sensitivity and whole body energy balance (138). Although it is
known that LCN2 expression can be highly induced and secreted from adipocytes and
LCN2 is significantly regulated in conditions of mouse and human obesity, the
mechanisms involved in this induction are poorly understood. LCN2 protein levels are
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Figure 2.19. IFNγ and TNFα induce LCN2 expression in human adipocytes. Human
subcutaneous adipocytes, purchased from Zenbio, were treated with 100 ng/ml IFNγ or
0.5 nM TNFα. Whole cell extracts were harvested after 24h. Time 0 indicates no
treatment. 150μg of whole cell extracts were subjected to western blot analysis. 300μg
protein was used to perform immunoprecipitation with human LCN2 antibody. IP
products were analyzed by western blot with human LCN2 antibody.

Table 7. Sequences of potential transcription factor binding sites in murine and human
LCN2 promoter
Murine
(ENSMUST00000050785)

STAT1
(TTCN2-4GAA)

NF-κB
(GGGNNNNNCC)

Human
(ENST00000277480)

-619

TTCCAGGATAAT

-856

TTCAATGGAAAA

-676

TTCCTGTAAA

-885

TTCCAGAACC

-1014

TTCAATTGAT

-1405

TTCCTGGGAA

-1822

TTCTTTGTAC

-1934

TTCCCGAGTA

-3171

TTCTGGAAGA

-3610

TTCCTGAGATG

-266

GGGAATGTCCC

-176

GGGAATGTCCC
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elevated in ob/ob mice and db/db mice (125), In agreement with these animal
experiments, human studies revealed that circulating LCN2 concentrations positively
correlate with adiposity, triglyceride concentration, blood glucose level and insulin
resistance (126;127). Yet, LCN2 is negatively related to high-density lipoprotein
cholesterol (127). However, there is very little information on the mechanisms involved
in the modulation of LCN2 expression. It has been reported that Interleukin-1 beta (IL1β) induces LCN2 expression through NF-κB and JAK2 mediated signaling pathways
(128). However, these observations are solely based on the use of inhibitors and no
binding sites or promoter activity was examined. Other studies indicate that expression
of LCN2 is up-regulated by agents that are associated with insulin resistance, including
lipopolysaccharide (LPS) (129), glucocorticoid (130), and insulin (146). Insulin
sensitizers, such as thiazolidinedione, down-regulate LCN2 expression (131). Our
studies provide the first mechanistic data on the identification and binding of two
transcription factors (STAT1 and NF-κB subunit p65) to the binding sites of the LCN2
promoter in vitro and in vitro. These results also reveal a role of serine/threonine
kinases ERKs 1 and 2 on the induction of LCN2 by pro-inflammatory cytokines that can
be produced from immune cells in adipose tissue to inhibit insulin signaling and induce
insulin resistance in adipocytes.
Our studies demonstrate that IFNγ and TNFα, induce LCN2 expression in both
murine and human adipocytes. We provide evidence that STAT1 plays a role in the
effects of IFNγ, while TNFα induces LCN2 expression via NF-κB signaling pathways.
Sequence analysis of the LCN2 promoter identified nine potential STAT binding sites
and three potential NF-κB binding sites. Binding of these transcription factors was
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assessed by both EMSA and ChIP analysis. These studies revealed the binding activity
of a NF-κB site and five STAT1 binding sites in the LCN2 promoter. Transfection
experiments with a promoter construct confirmed that the region containing these
binding sites in LCN2 promoter mediated the increase of gene expression after IFNγ
and TNFα treatment. Moreover, inhibition of ERKs 1 and 2 activation attenuated the
stimulatory effects of both cytokines. Our data suggest that ERKs signaling is required
for the maximal transactivation activity of STAT1 and NF-κB, but ERKs inhibition did not
have a significant effect on nuclear localization or DNA binding activity of these
transcription factors. Future studies will need to be performed to determine if ERKs
have direct effects on the serine phosphorylation of p65 or STAT1. Previous studies
have demonstrated that serine phosphorylation of STAT1 is required for its maximum
transactivation activity (147). Also, several serine phosphorylation sites have been
identified in NF-κB subunit p65 (148-152). Although our preliminary studies suggest
these transcription factors are serine phosphorylated by ERKs, we have not examined
whether this phosphorylation mediates the ERK-dependent effects on LCN2 expression.
Collectively, our findings suggest that the ERKs signaling pathways crosstalk with the
STAT1 and NF-κB signaling pathways in adipocytes.
One drawback related to our studies is that the functions of LCN2 still need to be
determined. Although several groups have studied LCN2 null mice, the results of these
studies are inconsistent. Previous research has shown important roles of LCN2 in the
transportation of hydrophobic molecules, in limiting bacterial growth (119) and
modulating degradation of the matrix turnover enzyme, MMP-9 (117). The versatile
functions of LCN2 make it difficult to assess the primary reason that accounts for the
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different phenotypes of the LCN2 null mice. Some data shows induction of PPARγ and
adiponectin by LCN2 (131) suggesting that LCN2 may be beneficial. Yet, other studies
indicate improved insulin action in LCN2 knockout cells (125), indicating that LCN2 is
associated with metabolic dysfunction. Although it is clear that LCN2 affects adipocyte
properties and participates in the regulation of insulin sensitivity, opposite effects of
LCN2 have been reported. Therefore, our studies on the regulation of LCN2 expression
have merit and allow us to speculate the inflammatory cytokines we have shown to
induce LCN2 may play a role in metabolic dysfunction.
In summary, LCN2 expression and secretion is induced by IFNγ and TNFα. Both
of these pro-inflammatory cytokines are likely pathological mediators of increased LCN2
expression that occurs in adipose tissue in conditions of insulin resistance in mouse and
man. Our mechanistic studies reveal that STAT1, NF-κB and ERKs signaling pathways
participate in the modulation of LCN2 expression in vitro and in vivo. Future studies will
be needed to determine if these transcriptional factors are essential for the induction of
LCN2.
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CHAPTER 3. THE INDUCTION OF LIPOCALIN-2 PROTEIN EXPRESSION IN VIVO
AND IN VITRO

3.1 Introduction
Adipose tissue produces cytokines and hormones that modulate energy
metabolism and systematic insulin sensitivity (138). Alterations in expression or
secretion of these secreted proteins from adipocytes can contribute to insulin resistance.
Chronic inflammation, accompanied by immune cell infiltration into adipose tissue, has
been shown to play an important role in the pathogenesis of insulin resistance (1;16).
Pro-inflammatory cytokines secreted by adipose tissue immune cells can affect
properties of adipocytes. Two major pro-inflammatory cytokines, IFNγ and TNFα, can
induce insulin resistance in adipocytes (15;33;44;140) and modulate the expression and
secretion of adipokines (19;32;153), including adiponectin (19;22), which is exclusively
expressed in mature adipocytes.
Lipocalin-2 (LCN2) belongs to the lipocalin family, a group of well-known
transporters of small hydrophobic molecules in circulation (116). LCN2 was initially
characterized as protein that interacts with and stabilizes matrix metalloproteinase 9
(117). LCN2 plays important roles in innate immune response by limiting bacterial
growth (118;119;145).

This chapter, THE INDUCTION OF LIPOCALIN-2 PROTEIN EXPRESSION IN VIVO AND IN VITRO,
previously appeared as Zhao P, Elks CM and Stephens JM. The induction of lipocalin-2 protein
expression in vivo and in vitro, J Biol Chem. 2014. It is reprinted by permission of the American Society
for Biochemistry and Molecular Biology.
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More recent studies have shown that LCN2 is a novel adipokine that is upregulated in obese and type 2 diabetic subjects (125). However, the roles of LCN2 in
modulating insulin sensitivity are still unclear. Studies of global LCN2 knockout mice
from separate groups have reported divergent phenotypes (132-134). Given the
versatile functions of LCN2, it is not surprising that the phenotypes of global knockout
mice are inconsistent. Although the role of LCN2 in modulation of insulin action is not
clear, it is clear that LCN2 is produced in adipocytes and regulated in murine and
human obesity (125-127). In one study, administration of LCN2 induced PPARγ and
adiponectin expression and ameliorated the negative effects of TNFα in 3T3-L1
adipocytes (131). Recently, LCN2 has been shown to be highly expressed in inguinal fat
and to significantly affect HFD-induced adipose tissue expandability in a depot-specific
manner (135). In this study, the absence of LCN2 expression significantly enhanced
high fat diet (HFD)-induced inguinal fat expansion. Yet, compared to wild type mice,
HFD-induced epididymal fat expansion in LCN2 deficient mice was significantly
decreased (135). Although some observations suggest a potentially metabolically
protective role of LCN2, there are substantial inconsistent observations related to
actions of LCN2 in relation to glucose tolerance and insulin sensitivity (132-134).
Despite the positive correlations of expression and circulating levels of LCN2 with
obesity and insulin resistance (126;127), the underlying mechanism mediating the
induction of LCN2 is still unknown. Here, we report that IFNγ and TNFα induce LCN2
expression and secretion in vivo. Using knockdown methodology, we have shown that
STAT1 and NF-κB are required for the induction of LCN2 by pro-inflammatory cytokines.
Our previous observations demonstrated that ERKs signaling also contributes to the
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IFNγ- and TNFα-induced expression of LCN2 (153). Our new results reveal that ERKs 1
and 2 activation affects the serine phosphorylation of STAT1 and NF-κB at specific sites.
These studies suggest that STAT 1 Ser727 phosphorylation plays a role in the additive
effects of IFNγ and TNFα on LCN2 expression in adipocytes. Moreover, we have
identified several STAT1 and NF-κB binding sites in the human LCN2 promoter,
suggesting some translational relevance to our mechanistic studies. Collectively, our
data demonstrates that IFNγ and TNFα are capable of inducing LCN2 from several
insulin-sensitive tissues in vivo, and provides insight into the interplay between ERKs
and STAT1 or NF-κB signaling pathways in adipocytes.
3.2 Experimental Procedures
Animal
Procedures for animal studies were approved by the Pennington Biomedical
Research Center Institutional Animal Care and Use Committee. Adult male C57BL/6J
mice were purchased from The Jackson Laboratory. All mice were housed in groups of
three or four, and had free access to water and standard chow (Purina LabDiet 5001).
IFNγ and TNFα (R&D Systems) were dissolved in a sterile PBS with 0.1% BSA vehicle
solution. 10-week old male mice (~25g) were injected intraperitoneally (i.p.) with 0.2 ml
vehicle, IFNγ (1.25mg/kg body weight), TNFα (0.05mg/kg body weight), or both
cytokines. Mice were euthanized by CO2 gas inhalation 3 hrs or 14 hrs post-injection.
Tissues were removed, immediately frozen in liquid nitrogen, and stored at -80°C. Blood
was collected into serum separator tubes, allowed to clot at room temperature, and
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centrifuged at 1,500g for 15min at 4°C. The supernatant (serum) was then transferred to
a clean tube and stored at -80°C for later analysis.
Cell culture
Murine 3T3-L1 preadipocytes were grown in Dulbecco’s Modified Eagle’s Media
(DMEM) containing 10% bovine serum. Two days after confluence, 0.5 mmol/l 3isobutyl-methylxanthine, 1 μmol/l dexamethasone, and 1.7 μmol/l insulin (MDI) cocktail
were added to induce preadipocytes differentiation in DMEM with 10% fetal bovine
serum (FBS). Media was changed to DMEM with 10% FBS 48h later. DMEM was from
Sigma. Bovine serum and FBS were from Hyclone. Human subcutaneous adipocytes in
6-well plates were from Zen-Bio. Recombinant mouse and human IFNγ were purchased
from R&D Systems. Recombinant mouse and human TNFα were purchased from Gibco.
UO126 was purchased from Promega.
Small interfering RNA-mediated knockdown
3T3-L1 adipocytes were trypsinized and re-plated in 24-well plates. Cells were
transfected using DharmaFECT Duo (Thermo-Dharmacon) reagent and 100nM siRNA
(Thermo-Dharmacon). Non-targeting siRNA was used as negative control. After 24hrs,
cells were harvested for RNA analysis and assessment of transfection efficiency.
RNA analysis
Tissues were homogenized in Trizol (Qiagen). Cell monolayers were harvested
in RLT lysis buffer. Total RNA was isolated from homogenized tissues or harvested
cells with a RNeasy mini kit (Qiagen). 10μl of purified RNA was used for reverse
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transcription PCR to generate cDNA. Delta delta ct real-time PCR with SYBR supermix
reagent (Takara) and an Applied Biosystems 7900HT system were used to analyze
cDNA. Cyclophilin A was used as an endogenous control. The following primers were
used for the real-time PCR: mCyclophilin A forward CCACTGTCGCTTTTCGCCGC and
reverse TGCAAACAGCTCGAAGGAGACGC; mLCN2 forward TGCAAGTGGCCACCA
CGGAG and reverse GCATTGGTCGGTGGGGACAGAGA.
Preparation of whole cell extracts
3T3-L1 adipocytes were harvested in non-denaturing IP buffer containing
10 mmol/l Tris (pH 7.4), 150 mmol/l NaCl, 1 mmol/l EGTA, 1 mmol/l EDTA, 1% Triton X100, 0.5% Nonidet P-40, with protease inhibitors 1 μmol/l phenylmethylsulfonyl fluoride,
1 μmol/l pepstatin, 50 mU trypsin inhibitory aprotinin, 10 μmol/l leupeptin, and
phosphatase inhibitor 2 mmol/l sodium vanadate. Cell monolayers were scraped off the
plates. Each extract was needled three times and centrifuged at 9500g for 10min at 4°C.
Supernatants were then transferred to new tubes and analyzed with BCA (Pierce) to
measure protein concentration.
Gel electrophoresis and immunoblotting
Proteins were separated on 7.5% or 10% gels by SDS-PAGE and transferred to
nitrocellulose membranes. Membranes were blocked in 4% milk for 1h, and then
incubated with primary antibody overnight at 4°C. After incubation with HRP-conjugated
secondary

antibodies

(Jackson

ImmunoResearch

Laboratory),

enhanced

chemiluminescence reagents (Pierce) were used to visualize results. The LCN2
antibody was purchased from R&D Systems. ERK1/2, STAT5A, p65Ser276 antibodies
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were from Santa Cruz Technology. The adiponectin antibody was from Thermo-Pierce.
STAT1, STAT1Tyr701, STAT1Ser727, STAT5, p65, p65Ser536, MCP-1 antibodies
were from Cell Signaling Technology. The active ERK1/2 antibody was from Promega.
Chromatin immunoprecipitation
A SimpleChIP® Enzymatic Chromatin IP Kit (Cell Signaling Technology) was
used for the ChIP assay. Human subcutaneous adipocytes were serum-deprived
overnight. Cells were treated with recombinant human cytokines for 30min, and then
cross-linked with formaldehyde and glycine. Chromatin extracts were prepared
according

to

the

manufacturer’s

protocol.

STAT1

and

p65

antibodies

for

immunoprecipitation were purchased from Cell Signaling. Purified DNA was quantified
by real-time PCR with SYBR green supermix and ROX buffer (Takara). Primer
sequences for real-time PCR: -176 forward GAAACAGCACAAGGAAGGCACAGA and
reverse

CCTGCGGAAACACTTGGCAAGATT;

-856

forward

ATAACTGCTTCC

CTGCTGGACAAG and reverse GGCCTTATCCTTGAGGTCACTGAG; -1405 forward
CGGCCTGGCAGAGGATACTTTTTA and reverse GTTGCACCAAAGCCTTCCCTTTCT;
-1934 forward GCCTCCCAGGTTCAAGCAATTCTT and reverse CAAAGATTAGTTG
GGCATGGTGGC; -3610 forward CCACGCTGAACACTACTCACAAGA and reverse
TGCATGAAGGCAGCAAGATGCTTC. Formula used to calculate percentage of input:
Percentage of input=2%×2(C[T] 2% input sample−C[T] IP sample)
Statistical analysis
All data were analyzed by two-tailed unpaired Student’s t-test. Data of animal
experiments are presented as mean±SEM. Results from studies of cultured adipocytes
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are shown as mean±SD. Results were considered statistically significant when p<0.05
(#, p<0.1; *, p<0.05; **, p<0.01; ***, p<0.001 vs. Control).
3.3 Results
LCN2 expression and secretion are induced by pro-inflammatory cytokines in vivo
Several studies have shown that LCN2 is induced in obesity/T2DM (125-127)
and we have shown that both IFNγ and TNFα induce LCN2 in cultured murine and
human adipocytes (153). However, the ability of these cytokines to induce LCN2 in the
whole animal has not been investigated. To determine the ability of these cytokines to
modulate LCN2 in vivo, 10-week old male C57BL/6J mice were injected i.p. with IFNγ or
TNFα. After 14 hrs, the mice were sacrificed and epididymal fat pads were collected. As
shown in Figures 3.1, both IFNγ and TNFα increase LCN2 mRNA levels in epididymal
WAT. To determine if these cytokines could modulate circulating levels of LCN2, we
also collected serum from these mice. As shown in Figure 3.2, IFNγ and TNFα
increased circulating levels of LCN2.
LCN2 is an adipokine, but is also known to be expressed in other tissues.
Therefore, we examined the ability of IFNγ and TNFα to induce LCN2 expression in
other insulin-sensitive tissues. In this experiment, C57BL/6J mice were injected i.p. with
IFNγ, TNFα or both of these cytokines. Our previous studies demonstrated that IFNγ
and TNFα had an additive effect on the induction of LCN2 in cultured adipocytes (153).
As shown in Figure 3.3-3.7, IFNγ, TNFα and the combination of both cytokines
treatments significantly induced LCN2 expression in epididymal WAT (Figure 3.3), liver
(Figure 3.5) and heart (Figure 3.6) three hours after cytokine injection. The combination
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Figure 3.1. IFNγ and TNFα induce LCN2 expression and secretion in vivo. 10-week old
male C57BL/6J mice were injected i.p. with IFNγ (1.25 mg/kg body weight) or TNFα
(0.05mg/kg body weight) and euthanized 14 hrs later. Total RNA in epididymal WAT
was purified and analyzed by real-time PCR. Cyclophilin A was used as endogenous
control. Data are shown as mean±SEM, n=4 mice/condition.*, p<0.05; **, p<0.01; ***,
p<0.001.

Figure 3.2. IFNγ and TNFα induce LCN2 expression and secretion in vivo. 10-week old
male C57BL/6J mice were injected i.p. with IFNγ (1.25 mg/kg body weight) or TNFα
(0.05mg/kg body weight) and euthanized 14 hrs later. 250μg serum protein was
subjected to western blot analysis. Western blot results were quantified with Image J.
The quantification is in the bottom panel. Data are shown as mean±SEM, n=4
mice/condition. *, p<0.05; **, p<0.01; ***, p<0.001.
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of both cytokines caused a more robust elevation of LCN2 mRNA and provides novel
data demonstrating that IFNγ and TNFα have additive effects on LCN2 expression in
vivo. Treatment with either IFNγ or TNFα did not significantly induce LCN2 expression
in inguinal WAT (Figure 3.4) or medial gastrocnemius (Figure 3.7). However, the
combination treatment did significantly increase LCN2 in both of these tissues. As
indicated in Table 8, epididymal WAT is the tissue that primarily responds to IFNγ
treatment, as indicated by an increase in the LCN2 mRNA level of ~15-fold. However,
liver was the most sensitive to TNFα treatment and resulted in an elevation of LCN2
mRNA levels by more than 2000-fold. Collectively, these experiments indicate that IFNγ
and TNFα differentially modulate LCN2 expression in a tissue-specific manner and have
additive effects in vivo.

Figure 3.3. IFNγ and TNFα differentially induce LCN2 expression in different tissues.
10-week old male C57BL/6J mice were injected i.p. with IFNγ (1.25 mg/kg body weight),
TNFα (0.05 mg/kg body weight), or both, and euthanized 3 hrs later. Total RNA in
epididymal WAT was isolated and analyzed by real-time PCR. Cyclophilin A was used
as endogenous control. Data are presented as mean±SEM, n=3 mice/condition. #, p<0.1;
*, p<0.05; **, p<0.01; ***, p<0.001.
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Figure 3.4. IFNγ and TNFα differentially induce LCN2 expression in different tissues.
10-week old male C57BL/6J mice were injected i.p. with IFNγ (1.25 mg/kg body weight),
TNFα (0.05 mg/kg body weight), or both, and euthanized 3 hrs later. Total RNA in
inguinal WAT was isolated and analyzed by real-time PCR. Cyclophilin A was used as
endogenous control. Data are presented as mean±SEM, n=3 mice/condition. #, p<0.1; *,
p<0.05; **, p<0.01; ***, p<0.001.

Figure 3.5. IFNγ and TNFα differentially induce LCN2 expression in different tissues.
10-week old male C57BL/6J mice were injected i.p. with IFNγ (1.25 mg/kg body weight),
TNFα (0.05 mg/kg body weight), or both, and euthanized 3 hrs later. Total RNA in liver
was isolated and analyzed by real-time PCR. Cyclophilin A was used as endogenous
control. Data are presented as mean±SEM, n=3 mice/condition. #, p<0.1; *, p<0.05; **,
p<0.01; ***, p<0.001.
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Figure 3.6. IFNγ and TNFα differentially induce LCN2 expression in different tissues.
10-week old male C57BL/6J mice were injected i.p. with IFNγ (1.25 mg/kg body weight),
TNFα (0.05 mg/kg body weight), or both, and euthanized 3 hrs later. Total RNA in heart
was isolated and analyzed by real-time PCR. Cyclophilin A was used as endogenous
control. Data are presented as mean±SEM, n=3 mice/condition. #, p<0.1; *, p<0.05; **,
p<0.01; ***, p<0.001.

Figure 3.7. IFNγ and TNFα differentially induce LCN2 expression in different tissues.
10-week old male C57BL/6J mice were injected i.p. with IFNγ (1.25 mg/kg body weight),
TNFα (0.05 mg/kg body weight), or both, and euthanized 3 hrs later. Total RNA in
gastrocnemius was isolated and analyzed by real-time PCR. Cyclophilin A was used as
endogenous control. Data are presented as mean±SEM, n=3 mice/condition. #, p<0.1; *,
p<0.05; **, p<0.01; ***, p<0.001.
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Table 8. IFNγ and TNFα-induced LCN2 expression in different tissues
IFNγ

TNFα

IFNγ+TNFα

Epididymal WAT

17-fold**

26-fold**

86-fold***

Inguinal WAT

n.s.

n.s.#(P=0.0875)

44-fold**

Liver

7-fold*

2175-fold*

4527-fold**

Heart

3-fold*

14-fold***

67-fold***

Gastrocnemius

n.s.

n.s.

9-fold**

( n.s., not significant; #, p<0.1; *, p<0.05; **, p<0.01; ***, p<0.001. )

NF-κB is required for TNFα induced LCN2 expression
Recent studies by our laboratory have shown that TNFα-induced NF-κB
activation results in binding of p65 to one site in the murine LCN2 promoter and
correlates with the induction of LCN2 expression (153). To determine the importance of
NF-κB signaling in the ability of TNFα to induce LCN2 expression in adipocytes we used
a knockdown approach. Small interfering-RNA targeting the p65 subunit of NF-κB was
transfected into mature 3T3-L1 adipocytes. As shown in Figure 3.8, p65 mRNA levels
were reduced by 60~70 percent with p65 siRNA transfection. Non-targeting siRNA was
used as negative control and had no effect on p65 mRNA expression. Two days after
transfection, adipocytes were serum-deprived overnight and then treated with TNFα for
16 hrs (for RNA analysis) or 24 hrs (for protein analysis). As expected, TNFα induced
LCN2 mRNA and protein in control adipocytes and in adipocytes transfected with nontargeting siRNA. However, the ability of TNFα to induce LCN2 mRNA (Figure 3.9) and
protein (Figure 3.10) was substantially reduced in cells transfected with p65 siRNA.
STAT5A was used as a protein loading control. We also examined the expression level
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of MCP-1, an inflammatory marker that can be induced by TNFα and secreted by
adipocytes. The TNFα mediated induce of MCP-1 was also substantially decreased by
p65 knockdown.

Figure 3.8. NF-κB is required for TNFα-induced LCN2 expression in adipocytes. 3T3-L1
adipocytes were transfected with 100nM non-targeting siRNA or p65 siRNA. 24 hrs later,
total RNA was purified and analyzed by real-time PCR. Cyclophilin A was used as
endogenous control. ***, p<0.001.

Figure 3.9. NF-κB is required for TNFα-induced LCN2 expression in adipocytes. 3T3-L1
adipocytes were transfected with 100nM non-targeting siRNA or p65 siRNA. After 40hrs,
cells were serum-deprived for 24hrs, and treated with 0.5nM TNFα. Total RNA was
isolated 16hrs later, and subjected to quantitative real-time PCR. Cyclophilin A was
used as endogenous control. ***, p<0.001.
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Figure 3.10. NF-κB is required for TNFα-induced LCN2 expression in adipocytes. 3T3L1 adipocytes were transfected with 100nM non-targeting siRNA or p65 siRNA. 40hrs
after transfection, adipocytes were serum-deprived for 24hrs, and treated with 0.5nM
TNFα. Whole cell extract was harvested after 24hrs. 150 μg protein was analyzed by
western blot.

STAT1 is required for IFNγ induced LCN2 expression
Our recent studies have also shown that IFNγ-induced LCN2 expression
correlates with the binding of STAT1 to five sites in the murine LCN2 promoter (153). To
determine if IFNγ-activated STAT1 was required for the induction of LCN2 in adipocytes,
we used a siRNA knockdown approach. STAT1 mRNA was decreased by ~60 percent
with STAT1 knockdown (Figure 3.11). Transfection of non-targeting siRNA had no effect
on STAT1 mRNA level. Two days after transfection, mature adipocytes were serum
deprived and treated with IFNγ for 16 hrs (for RNA analysis) or 24 hrs (for protein
analysis). As previously reported, IFNγ treatment induced LCN2 mRNA (Figure 3.12)
and protein levels (Figure 3.13) in 3T3-L1 adipocytes. Moreover, the induction of LCN2
was significantly reduced in adipocytes that had less STAT1. STAT1 knockdown had no
effect on STAT5 proteins in adipocytes (Figure 3.13). It is known that IFNγ can induce
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MCP-1 in human mesangial cells (154); we observed a similar induction of MCP-1 in
3T3-L1 adipocytes following IFNγ treatment. However, STAT1 knockdown did not affect
IFNγ-induced MCP-1 expression.

Figure 3.11. STAT1 is necessary for IFNγ-induced LCN2 expression in adipocytes. 3T3L1 adipocytes were transfected with 100nM STAT1 siRNA or non-targeting siRNA.
24hrs later, total RNA was purified and analyzed by real-time PCR. Cyclophilin A was
used as endogenous control. ***, p<0.001.

Figure 3.12. STAT1 is necessary for IFNγ-induced LCN2 expression in adipocytes. 3T3L1 adipocytes were transfected with 100nM STAT1 siRNA or non-targeting siRNA. After
40hrs, cells were serum-deprived for 24hrs, and treated with 100ng/ml IFNγ. Total RNA
was isolated 16hrs later, and subjected to quantitative real-time PCR. Cyclophilin A was
used as endogenous control. ***, p<0.001.
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Figure 3.13. STAT1 is necessary for IFNγ-induced LCN2 expression in adipocytes. 3T3L1 adipocytes were transfected with 100nM STAT1 siRNA or non-targeting siRNA.
40hrs after transfection, adipocytes were serum-deprived for 24hrs, and treated with
100ng/ml IFNγ. Whole cell extracts were obtained after 24 hrs and 150 μg protein was
analyzed by western blot. ***, p<0.001.

TNFα- and IFNγ-induced ERKs signaling modulates the serine phosphorylation of
STAT1 and p65
Our recent studies on LCN2 have shown that the induction of this adipokine by
both IFNγ and TNFα is dependent on ERKs activation (153). Hence, we wanted to
investigate how ERKs signaling contributes to the effects of these cytokines. There is
evidence to suggest that serine phosphorylation of NF-κB (148;150;155) and STAT1
(147;156) plays a role in transcriptional activity of these signaling proteins. Therefore,
we examined the phosphorylation of STAT1 at Ser727 and p65 at Ser536 to determine the
effects of IFNγ or TNFα treatment on phosphorylation. Fully differentiated 3T3-L1
adipocytes were acutely treated (15 min.) with IFNγ, TNFα or both cytokines. As shown
in Figure 3.14, IFNγ and TNFα activate the ERKs 1 and 2 signaling pathways in
adipocytes. Of note, TNFα treatment in the presence or absence of IFNγ induced
phosphorylation of Ser536 on p65. However, IFNγ did not modulate p65 serine
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phosphorylation at this site. IFNγ did induce STAT1 tyrosine phosphorylation. All
treatments induced STAT1 Ser727 phosphorylation. The data clearly indicate an additive
effect of IFNγ and TNFα on STAT1Ser727 phosphorylation.

Figure 3.14. Regulation of the ERKs signaling pathway and STAT1 and NF-κB serine
phosphorylation by IFNγ and TNFα. Mature adipocytes were treated with IFNγ
(100ng/ml), TNFα (0.5nM) or combo for 15min. Whole cell extracts were prepared and
150 μg protein was subjected to western blot analysis.
NF-κB signaling studies have also revealed that p65 can be phosphorylated on
Ser276 by activation of PKA (155). Therefore, we also examined p65 Ser276
phosphorylation. Forskolin, a PKA activator, was used as a positive control in these
experiments. As shown in Figure 3.15, neither IFNγ nor TNFα had effect on p65Ser276.
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Nonetheless, we examined the ability of p65 Ser276 phosphorylation to influence LCN2
expression. Mature adipocytes were treated with TNFα or forskolin for 16 hrs. TNFα
induced LCN2 expression, whereas forskolin decreased LCN2 expression (Figure 3.16).
These results suggest that phosphorylation of p65 Ser276 does not participate in the
induction of LCN2 expression.

Figure 3.15. Regulation of the ERKs signaling pathway and STAT1 and NF-κB serine
phosphorylation by IFNγ and TNFα. Cells were treated with IFNγ (100ng/ml), TNFα
(0.5nM) or forskolin (20μM) for 15min. Whole cell extracts were harvested, and 150 μg
protein was analyzed by western blot.

Figure 3.16. Regulation of the ERKs signaling pathway and STAT1 and NF-κB serine
phosphorylation by IFNγ and TNFα. 3T3-L1 adipocytes were treated with TNFα (0.5nM)
or forskolin (20μM) for 16hrs. Total RNA was isolated and subjected to real-time PCR
analysis. Cyclophilin A was used as endogenous control. These data are from
representative experiments performed with three different batches of cells. ***, p<0.001.
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Since our results suggested that serine phosphorylation may play a role in the
additive effects of TNFα or IFNγ on LCN2 expression, we assessed whether the
activation of ERKs was required for serine phosphorylation of p65 and STAT1. Mature
3T3-L1 adipocytes were pretreated with the highly specific ERK inhibitor UO126 for 30
min and then exposed to TNFα or IFNγ for an additional 15 min. As expected, ERKs
activation was inhibited by UO126 pretreatment. We observed that TNFα-induced p65
Ser536 phosphorylation was eliminated by inhibition of ERKs (Figure 3.17). This data
suggests that ERKs directly mediate Ser536 phosphorylation of p65. Although UO126
pretreatment had no effect on IFNγ-induced STAT1 tyrosine phosphorylation, both
IFNγ- and TNFα-induced serine phosphorylation of STAT1 were abolished by ERKs
inhibition (Figure 3.18).

Figure 3.17. Activation of ERKs is required for serine phosphorylation of NF-κB
p65Ser536 and STAT1Ser727. 3T3-L1 adipocytes were pretreated with 50μM ERKs
inhibitor UO126 for 30min, and then treated with 0.5nM TNFα for 15min. Whole cell
extracts were isolated. 150 μg protein was analyzed by western blot.

63

Figure 3.18. Activation of ERKs is required for serine phosphorylation of NF-κB
p65Ser536 and STAT1Ser727. Adipocytes were treated with 100ng/ml IFNγ or 0.5nM
TNFα in presence or absence of 50μM UO126. Whole cell extracts were harvested and
150 μg protein was subjected to western blot analysis.

Identification of STAT1 and NF-κB binding sites in human LCN2 promoter
As indicated above, our recent efforts have identified one NF-κB and several
STAT1 binding sites in the murine LCN2 promoter (153). Hence, we performed an in
silico analysis to identify potential STAT1 and NF-κB binding sites in human LCN2
promoter (Table 9). The four potential STAT1 binding sites and one potential NF-κB
binding site were examined by ChIP assays. Human subcutaneous adipocytes were
treated with recombinant human IFNγ or TNFα for 30 min. ChIP assays were performed
with specific STAT1 and p65 antibodies. As shown in Figure 3.19, we observed that all
four potential STAT binding sites were capable of interacting with STAT1 in an IFNγinduced manner in human fat cells in vivo. In addition, we observed TNFα-induced p65
binding to a NF-κB binding site in the human LCN2 promoter in human adipocytes
(Figure 3.20).
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Table 9. STAT1 and NF-κB binding sites in human LCN2 promoter.
Human LCN2
(ENST00000277480)

STAT1
(TTCN2-4GAA)

NF-κB
(GGGNNNNNCC)

-856

TTCAATGGAAAA

-1405

TTCCTGGGAA

-1934

TTCCCGAGTA

-3610

TTCCTGAGATG

-176

GGGAATGTCCC

Figure 3.19. Identification of STAT1 binding sites in the human LCN2 promoter. Human
subcutaneous adipocytes were treated or untreated with 100ng/ml recombinant human
IFNγ for 30 min, and then cross-linked with formaldehyde. Chromatin extracts were
prepared and immunoprecipitated with STAT1 antibody. IP products were subjected to
quantitative real-time PCR analysis. Percentage of input was calculated and normalized
to the control group. ***, p<0.001.
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Figure 3.20. Identification of an NF-κB binding site in the human LCN2 promoter.
Human subcutaneous adipocytes were untreated or treated with 0.5nM recombinant
human TNFα for 30min, and cross-linked with formaldehyde. Chromatin extracts were
isolated and subjected to immunoprecipitation with NF-κB p65 antibody. IP products
were analyzed by real-time PCR. Percentage of input was calculated and normalized to
the control. ***, p<0.001.

3.4 Discussions
Chronic inflammation in adipose tissue is associated with insulin resistance
(1;16). Pro-inflammatory cytokines secreted by immune cells that are present in adipose
tissue can affect the functions of adipocytes, including insulin sensitivity and endocrine
functions. The adipokine LCN2 is significantly elevated in obese and diabetic subjects
(126;127) and studies in animal models demonstrate increased LCN2 in the adipose
tissue of ob/ob and db/db mice (125). Despite the profound induction of LCN2 in obesity
in mice and man, the underlying mechanisms mediating these effects are largely
unknown. Our studies show that IFNγ and TNFα are able to induce LCN2 expression in
vitro (153) and we have now demonstrated profound modulation of LCN2 in vivo. We
observed that IFNγ and TNFα induced LCN2 in the primary insulin sensitive tissues:
adipose tissue, skeletal muscle and liver. These studies also provide the first in vivo
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evidence to support the hypothesis that immune cell-derived inflammatory cytokines
may be responsible for the increase of LCN2 expression in obesity and type 2 diabetes.
Our studies also reveal tissue specific responses. IFNγ treatment affected LCN2
expression primarily in epididymal WAT, whereas LCN2 modulation in liver was most
sensitive to TNFα. We did not observe a significant increase of LCN2 in inguinal WAT or
gastrocnemius in mice treated with IFNγ or TNFα. However, there was a significant
cooperative effect of IFNγ and TNFα on LCN2 induction in most tissues examined.
These are the first studies to demonstrate such an effect in vivo. In our studies, we
delivered cytokines via i.p. injection. Since inguinal WAT and gastrocnemius are not in
the abdominal cavity, the lack of response in these tissues could be due to their
physical distance from the injection site, which may lead to limited responsiveness to
this specific method of cytokine treatment. It is possible that intravenous administration
of the cytokines could produce different responses in these two tissues.
Our previous studies suggested that STAT1 mediates IFNγ-induced LCN2
expression and that NF-κB plays a role in TNFα-mediated induction of LCN2 in cultured
adipocytes (153). However, both of these cytokines activate other signaling pathways,
so we investigated the dependence of STAT1 or the p65 subunit of NF-κB by
performing siRNA-mediated knockdown of these two transcription factors. Our results
demonstrated that STAT1 knockdown significantly attenuates IFNγ-induced LCN2
expression, while p65 knockdown ameliorates the induction effects of TNFα. These
observations demonstrate that IFNγ-induced LCN2 expression is largely mediated by
STAT1 and that TNFα requires NF-κB to induce LCN2 expression in adipocytes. There
is some additional specificity in our observations as the knockdown of p65 also inhibited
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TNFα-induced MCP-1 expression, but STAT1 knockdown did not affect the ability of
IFNγ to induce MCP-1. It is not surprising that loss of STAT1 or p65 does not
completely abolish the induction of LCN2 expression since siRNA-mediated knockdown
of these transcription factors reduced, but did not abolish, their expression levels.
Although LCN2 expression is likely affected by other transcription factors, our
observations strongly suggest that STAT1 and p65 are critical for the induction of LCN2
by IFNγ and TNFα.
Our previous studies on LCN2 revealed that ERKs 1 and 2 signaling was
required for the induction of LCN2 expression by IFNγ and TNFα in adipocytes (153).
To follow up on these studies, we examined serine phosphorylation of STAT1 and the
p65 subunit of NF-κB.

Some studies suggest that STAT1Ser727 phosphorylation

contributes to the maximal transactivation activity of STAT1 (147). The NF-κB p65
subunit can be phosphorylated at Ser276 (152;155) and Ser536 (148;150). However, the
functions of these phosphorylated serines are controversial. ERKs 1 and 2 are
serine/threonine kinases activated by both IFNγ (142) and TNFα (144). We
hypothesized that IFNγ- and TNFα-induced activation of ERKs may contribute to the
serine phosphorylation of both STAT1 and NF-κB in adipocytes. Our results clearly
show that phosphorylation of STAT1 Ser727 and p65Ser536 are mediated by activation of
ERKs 1 and 2. However, neither IFNγ nor TNFα treatment affected phosphorylation of
p65Ser276. As expected, the PKA activator forskolin induced p65Ser276 phosphorylation,
but it did not increase LCN2 expression. Forskolin treatment decreased LCN2
expression in adipocytes. These results indicate that p65Ser276 phosphorylation does
not participate in the profound stimulatory effects of IFNγ and TNFα on LCN2
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expression in adipocytes. The phosphorylation of p65Ser536 is induced by TNFα, but not
enhanced in the presence of IFNγ. However, STAT1Ser727 phosphorylation is much
greater in the presence of IFNγ and TNFα when compared to individual cytokine
treatments. Our study also supports data that IFNγ-induced STAT1 serine
phosphorylation is not dependent on tyrosine phosphorylation (157). Although we
observed TNFα-induced STAT1Ser727 phosphorylation, we did not observe any effect
on STAT1 tyrosine phosphorylation under these conditions. There is no doubt that the
combination of IFNγ and TNFα had a cooperative effect on STAT1Ser727
phosphorylation and LCN2 expression. Although TNFα does not result in the tyrosine
phosphorylation of STAT1, our results strongly suggest that TNFα-induces ERKs 1 and
2 phosphorylation of STAT1Ser727 that mediates a cooperative effect between IFNγ or
TNFα on LCN2 gene expression. It should be noted that these cytokines can modulate
other signaling proteins and the cooperative effects on LCN2 expression may be
influenced by ERK-independent pathways or other phosphorylation events. However,
based on our previous studies on LCN2 (153) and our current results, we propose that
STAT1Ser727 mediates cytokine cooperativity and that there is minimal contribution from
other signaling pathways in the regulation of LCN2 in fat cells.
In summary, our study shows that the pro-inflammatory cytokines IFNγ and TNFα
induce LCN2 expression and secretion in vivo. The presence of both cytokines results
in an additive effect on LCN2 expression. STAT1 is required for IFNγ-induced LCN2
expression, while NF-κB is necessary for the induction of both LCN2 and MCP-1 by
TNFα. ERKs signaling appears to contribute to the stimulatory effects of IFNγ and TNFα
via modulating serine phosphorylation of STAT1 and the p65 subunit of NF-κB. Four
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STAT1 binding sites and one NF-κB binding site were also identified in the human
LCN2 promoter, which suggests that our observations have translational relevance.
These studies provide insight into the ability of pro-inflammatory cytokines to regulate
adipocyte function. Although the roles of LCN2 in insulin resistance are still unclear, our
mechanistic studies on LCN2 expression do increase our understanding of the
modulation of this adipokine in conditions of obesity and type 2 diabetes.
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CHAPTER 4. SUMMARY AND FUTURE PLAN
4.1 Research Summary
Several studies in the last decade have shown that expression and secretion of
LCN2 is significantly up-regulated in obesity and insulin resistance in mice and man
(125-127). However, the mechanisms underlying how LCN2 expression is modulated
under these conditions are largely unknown. Our studies report that two proinflammatory cytokines induce LCN2 expression and secretion in cultured mouse and
human adipocytes. The induction of LCN2 is decreased by the inhibition of transcription
by actinomycin D. In mice, an intraperitoneal injection of IFNγ or TNFα induces LCN2
expression in multiple insulin sensitive tissues and increases circulating levels of LCN2.
The 2000-fold induction of LCN2 by TNFα in the liver did suggest that liver-secreted
LCN2 is likely responsible for its primary endocrine activities while LCN2 from adipose
tissue may be limited to paracrine functions. For both in vivo and in vitro experiments,
we observed an additive effect of IFNγ and TNFα on LCN2 expression. Our in vitro
signaling experiments have revealed that STAT1 and ERKs signaling pathways are
required for the induction of LCN2 expression by IFNγ. Our studies have also shown
that modulation of LCN2 by TNFα requires NF-κB and ERKs signaling pathways.
SiRNA-mediated knockdown of STAT1 attenuates IFNγ-induced elevation of LCN2
expression in adipocytes. Similarly, knockdown of NF-κB subunit p65 significantly
ameliorates the increase of LCN2 expression by TNFα. The inhibition of ERKs using the
pharmacological inhibitor UO126 ameliorates the induction effects of both IFNγ and
TNFα. These observations suggest that ERKs signaling also contributes to the induction
of LCN2 expression. Studies by other labs have shown that serine phosphorylation can
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affect the transcriptional activation activity of STAT1 (147) and NF-κB (148;152;155).
Serine727 is located in the TAD of STAT1 (158). A STAT1 S727A mutant has reduced
association with co-activator CREB-binding protein (CBP) (156). Similar to STAT1,
Serine536 is located in the TAD of p65. Phosphorylation of p65 Ser536 mediates its
association with CBP and dissociation with HDAC1 and 3 (148). Also, unphosphorylated
Ser536 and Asp533 can form a hydrogen bond, which is required for the interaction
between corepressor amino-terminal enhancer of split (AES) and p65 TAD (159).
Hence, we determined if active ERKs regulated the serine phosphorylation of STAT1
and p65 in adipocytes and/or the ability to modulate LCN2 expression. Our observations
clearly showed that activation of ERKs signaling is responsible for IFNγ and TNFαinduced serine phosphorylation of STAT1 and p65, respectively. IFNγ and TNFα also
have an additive effect on the serine phosphorylation of STAT1 and these data suggest
that this covalent modification may play a role in the additive effects of the proinflammatory cytokines on LCN2 expression.
Our in silico analysis of the LCN2 promoter revealed several potential STAT1
and NF-κB binding sites in the murine LCN2 promoter. By examining the interaction
between transcription factors and potential DNA binding sites with both electrophoretic
mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP), we confirmed
five STAT1 binding sites and one NF-κB binding site in the murine LCN2 promoter.
Pretreatment with an ERKs inhibitor showed no significant effects on either nuclear
translocation or DNA binding activity of either STAT1 or NF-κB. Our transfection studies
in 3T3-L1 adipocytes with plasmids containing the murine LCN2 promoter confirmed
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that inhibition of ERKs activation ameliorated the transcriptional activity of both STAT1
and NF-κB.
In order to determine if pro-inflammatory cytokines also induced LCN2
expression in humans, we used human subcutaneous adipocytes that we treated with
IFNγ or TNFα. Similar to our observations in murine fat cells, our results demonstrated
that both IFNγ and TNFα induced LCN2 expression in human adipocytes. Additional in
silico analyses revealed several potential STAT1 binding sites and NF-κB binding site in
the human LCN2 promoter. We confirmed all these DNA binding sites by performing by
ChIP analysis in human subcutaneous adipocytes. We also noted conservation of the
STAT1 binding sites between mice and humans. However, the NF-κB binding site was
completely conserved between mice and humans.
4.2 Significance of Research
Chronic inflammation has been shown to contribute to the pathogenesis of insulin
resistance. The pro-inflammatory cytokines produced from immune cells in adipose
tissues significantly affect the properties of adipocytes. LCN2 is a relatively new
adipokine that is highly expressed in adipocytes and significantly induced in obesity and
insulin resistance. However, the mechanisms involved in the modulation of LCN2
expression in pathological conditions were largely unknown. Our studies revealed that
LCN2 expression is modulated by IFNγ and TNFα, two important pro-inflammatory
cytokines and inducers of insulin resistance. Although the role of adipose tissue-derived
LCN2 in insulin resistance is still not clear, several studies have demonstrated that
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LCN2 affects functions of adipocytes and adipose tissue. Our observations increase the
knowledge of LCN2 expression in obese and insulin resistant subjects.
STAT1 and ERKs signaling pathways are utilized by IFNγ, and NF-κB and ERKs
pathways are adopted by TNFα in mature adipocytes to regulate LCN2 expression.
ERK signaling mediates the serine phosphorylation of STAT1 and NF-κB to regulate the
transactivation activity of both these transcription factors. These studies provide insight
regarding three distinct signaling pathways that are utilized by two important proinflammatory cytokines in mature adipocytes. These results enhance our understanding
about how chronic inflammation and pro-inflammatory cytokines modulate the function
and gene expression of adipocytes in conditions of metabolic dysfunction.
4.3 Future Plans
The primary limitation to our studies on LCN2 is that we do not fully understand
the role of LCN2 in the pathogenesis of insulin resistance. Previous studies of LCN2
global knockout mice showed completely different phenotypes (132-134), which further
contributes to our lack of understanding of LCN2 function. However, the reported
functions of LCN2 are highly versatile, a fact that likely accounts for the diverse
phenotypes of global knockout mice. According to unpublished data from Ronald Kahn’s
lab, the microbiota of mice is significantly changed when the animals are kept at
different facilities. There is mounting evidence to suggest that the variation of microbiota
could result in distinct phenotypes, even for mice that are genetically identical.
Considering the functions of LCN2 in limiting bacterial growth (118;119), global
knockout of LCN2 could exacerbate the variance of microbiota and significantly

74

contribute to the different phenotypes of LCN2 null mice that have been observed by
different laboratories. In addition, diet is a critical contributor to microbiota populations
(160;161). Hence, differences in the phenotypes of these animals could also be due to
different diets that impact microbiota.
Since the production of LCN2 significantly increases in insulin-resistant subjects,
future studies should focus on trying to determine the function of LCN2 produced by
adipocytes and adipose tissues. Studies have shown that expression of PPARγ and
adiponectin are elevated by LCN2 treatment (131). Recent publications have also
reported that LCN2 positively modulates fatty acid oxidation and energy expenditure
(136). Both of these studies suggest a protective role of LCN2 against obesity and
insulin resistance. Although we demonstrated that LCN2 expression is highly induced
by pro-inflammatory cytokines, it is possible that LCN2 mediates a negative feedback to
counteract the effects of pro-inflammatory cytokines on adipocytes. It would be
interesting to determine if LCN2 pretreatment can attenuate the impact of proinflammatory cytokine-activated signaling in mature adipocytes. Since LCN2 is
produced in several cell types, it would be important to assess the role of adipocytederived LCN2. This could be achieved by making an adipocyte-specific knockout of
LCN2 in mice and studying the mice in diabetic conditions.
It is known that LCN2 interacts with MMP-9, an important gelatinase that can
degrade elastin in matrix (162). Previous research has revealed that MMP-9 is also
increased in obese subjects (163). A recent study has also shown that elastin-derived
peptides, which are generated from the degradation of matrix elastin, have the
capability to modulate insulin sensitivity (164). Considering all this data, it would be
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logical to examine the possibility that LCN2 affects insulin sensitivity via regulating
matrix turnover. Future studies on LCN2 should focus on elucidating the functions of
this highly induced adipokine in relation to insulin resistance and other metabolic
disease states.

76

REFERENCES
1. Weisberg,SP, McCann,D, Desai,M, Rosenbaum,M, Leibel,RL, Ferrante,AW, Jr.:
Obesity is associated with macrophage accumulation in adipose tissue. J Clin
Invest 112:1796-1808, 2003.
2. Bastard,JP, Maachi,M, Lagathu,C, Kim,MJ, Caron,M, Vidal,H, Capeau,J, Feve,B:
Recent advances in the relationship between obesity, inflammation, and insulin
resistance. Eur Cytokine Netw 17:4-12, 2006.
3. Rosen,ED, Spiegelman,BM: Adipocytes as regulators of energy balance and
glucose homeostasis. Nature 444:847-853, 2006.
4. Zhang,Y, Proenca,R, Maffei,M, Barone,M, Leopold,L, Friedman,JM: Positional
cloning of the mouse obese gene and its human homologue. Nature 372:425-432,
1994.
5. Scherer,PE, Williams,S, Fogliano,M, Baldini,G, Lodish,HF: A novel serum protein
similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:2674626749, 1995.
6. Steppan,CM, Bailey,ST, Bhat,S, Brown,EJ, Banerjee,RR, Wright,CM, Patel,HR,
Ahima,RS, Lazar,MA: The hormone resistin links obesity to diabetes. Nature
409:307-312, 2001.
7. Green,H, Kehinde,O: An established preadipose cell line and its differentiation in
culture. II. Factors affecting the adipose conversion. Cell 5:19-27, 1975.
8. Green,H, Kehinde,O: Spontaneous heritable changes leading to increased
adipose conversion in 3T3 cells. Cell 7:105-113, 1976.
9. Green,H, Kehinde,O: Formation of normally differentiated subcutaneous fat pads
by an established preadipose cell line. J Cell Physiol 101:169-171, 1979.
10. Kopelman,PG: Obesity as a medical problem. Nature 404:635-643, 2000.
11. Leto,D, Saltiel,AR: Regulation of glucose transport by insulin: traffic control of
GLUT4. Nat Rev Mol Cell Biol 13:383-396, 2012.
12. Kahn,BB, Flier,JS: Obesity and insulin resistance. J Clin Invest 106:473-481,
2000.
13. Black,RA, Rauch,CT, Kozlosky,CJ, Peschon,JJ, Slack,JL, Wolfson,MF,
Castner,BJ, Stocking,KL, Reddy,P, Srinivasan,S, Nelson,N, Boiani,N,
Schooley,KA, Gerhart,M, Davis,R, Fitzner,JN, Johnson,RS, Paxton,RJ, March,CJ,
Cerretti,DP: A metalloproteinase disintegrin that releases tumour-necrosis factoralpha from cells. Nature 385:729-733, 1997.
77

14. Schroder,K, Hertzog,PJ, Ravasi,T, Hume,DA: Interferon-gamma: an overview of
signals, mechanisms and functions. J Leukoc Biol 75:163-189, 2004.
15. Hotamisligil,GS, Murray,DL, Choy,LN, Spiegelman,BM: Tumor necrosis factor
alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A
91:4854-4858, 1994.
16. Xu,H, Barnes,GT, Yang,Q, Tan,G, Yang,D, Chou,CJ, Sole,J, Nichols,A, Ross,JS,
Tartaglia,LA, Chen,H: Chronic inflammation in fat plays a crucial role in the
development of obesity-related insulin resistance. J Clin Invest 112:1821-1830,
2003.
17. Beutler,B, Greenwald,D, Hulmes,JD, Chang,M, Pan,YC, Mathison,J, Ulevitch,R,
Cerami,A: Identity of tumour necrosis factor and the macrophage-secreted factor
cachectin. Nature 316:552-554, 1985.
18. Doerrler,W, Feingold,KR, Grunfeld,C: Cytokines induce catabolic effects in
cultured adipocytes by multiple mechanisms. Cytokine 6:478-484, 1994.
19. Waite,KJ, Floyd,ZE, Arbour-Reily,P, Stephens,JM: Interferon-gamma-induced
regulation of peroxisome proliferator-activated receptor gamma and STATs in
adipocytes. J Biol Chem 276:7062-7068, 2001.
20. Lagathu,C, Yvan-Charvet,L, Bastard,JP, Maachi,M, Quignard-Boulange,A,
Capeau,J, Caron,M: Long-term treatment with interleukin-1beta induces insulin
resistance in murine and human adipocytes. Diabetologia 49:2162-2173, 2006.
21. Nohara,A, Okada,S, Ohshima,K, Pessin,JE, Mori,M: Cyclin-dependent kinase-5
is a key molecule in tumor necrosis factor-alpha-induced insulin resistance. J Biol
Chem 286:33457-33465, 2011.
22. Ruan,H, Hacohen,N, Golub,TR, Van,PL, Lodish,HF: Tumor necrosis factor-alpha
suppresses adipocyte-specific genes and activates expression of preadipocyte
genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is
obligatory. Diabetes 51:1319-1336, 2002.
23. Chavey,C, Lazennec,G, Lagarrigue,S, Clape,C, Iankova,I, Teyssier,J,
Annicotte,JS, Schmidt,J, Mataki,C, Yamamoto,H, Sanches,R, Guma,A, Stich,V,
Vitkova,M, Jardin-Watelet,B, Renard,E, Strieter,R, Tuthill,A, Hotamisligil,GS,
Vidal-Puig,A, Zorzano,A, Langin,D, Fajas,L: CXC ligand 5 is an adipose-tissue
derived factor that links obesity to insulin resistance. Cell Metab 9:339-349, 2009.
24. Keophiphath,M, Rouault,C, Divoux,A, Clement,K, Lacasa,D: CCL5 promotes
macrophage recruitment and survival in human adipose tissue. Arterioscler
Thromb Vasc Biol 30:39-45, 2010.

78

25. Nara,N, Nakayama,Y, Okamoto,S, Tamura,H, Kiyono,M, Muraoka,M, Tanaka,K,
Taya,C, Shitara,H, Ishii,R, Yonekawa,H, Minokoshi,Y, Hara,T: Disruption of CXC
motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance.
J Biol Chem 282:30794-30803, 2007.
26. Silva,LC, Ortigosa,LC, Benard,G: Anti-TNF-alpha agents in the treatment of
immune-mediated inflammatory diseases: mechanisms of action and pitfalls.
Immunotherapy 2:817-833, 2010.
27. Gupta,S, Gollapudi,S: Molecular mechanisms of TNF-alpha-induced apoptosis in
aging human T cell subsets. Int J Biochem Cell Biol 37:1034-1042, 2005.
28. Harris,J: Autophagy and cytokines. Cytokine 56:140-144, 2011.
29. De Taeye,BM, Novitskaya,T, McGuinness,OP, Gleaves,L, Medda,M,
Covington,JW, Vaughan,DE: Macrophage TNF-alpha contributes to insulin
resistance and hepatic steatosis in diet-induced obesity. Am J Physiol Endocrinol
Metab 293:E713-E725, 2007.
30. Hotamisligil,GS, Arner,P, Caro,JF, Atkinson,RL, Spiegelman,BM: Increased
adipose tissue expression of tumor necrosis factor-alpha in human obesity and
insulin resistance. J Clin Invest 95:2409-2415, 1995.
31. Kern,PA, Ranganathan,S, Li,C, Wood,L, Ranganathan,G: Adipose tissue tumor
necrosis factor and interleukin-6 expression in human obesity and insulin
resistance. Am J Physiol Endocrinol Metab 280:E745-E751, 2001.
32. Stephens,JM, Pekala,PH: Transcriptional repression of the GLUT4 and C/EBP
genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem
266:21839-21845, 1991.
33. Stephens,JM, Lee,J, Pilch,PF: Tumor necrosis factor-alpha-induced insulin
resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor
substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated
signal transduction. J Biol Chem 272:971-976, 1997.
34. Virkamaki,A, Ueki,K, Kahn,CR: Protein-protein interaction in insulin signaling and
the molecular mechanisms of insulin resistance. J Clin Invest 103:931-943, 1999.
35. Hotamisligil,GS, Peraldi,P, Budavari,A, Ellis,R, White,MF, Spiegelman,BM: IRS1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alphaand obesity-induced insulin resistance. Science 271:665-668, 1996.
36. Feinstein,R, Kanety,H, Papa,MZ, Lunenfeld,B, Karasik,A: Tumor necrosis factoralpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor
and its substrates. J Biol Chem 268:26055-26058, 1993.

79

37. Ozes,ON, Akca,H, Mayo,LD, Gustin,JA, Maehama,T, Dixon,JE, Donner,DB: A
phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN
antagonizes tumor necrosis factor inhibition of insulin signaling through insulin
receptor substrate-1. Proc Natl Acad Sci U S A 98:4640-4645, 2001.
38. Spiegelman,BM: PPAR-gamma: adipogenic regulator and thiazolidinedione
receptor. Diabetes 47:507-514, 1998.
39. Berg,AH, Combs,TP, Du,X, Brownlee,M, Scherer,PE: The adipocyte-secreted
protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953, 2001.
40. Hajri,T, Tao,H, Wattacheril,J, Marks-Shulman,P, Abumrad,NN: Regulation of
adiponectin production by insulin: interactions with tumor necrosis factor-alpha
and interleukin-6. Am J Physiol Endocrinol Metab 300:E350-E360, 2011.
41. Choi,JH, Banks,AS, Estall,JL, Kajimura,S, Bostrom,P, Laznik,D, Ruas,JL,
Chalmers,MJ, Kamenecka,TM, Bluher,M, Griffin,PR, Spiegelman,BM: Antidiabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.
Nature 466:451-456, 2010.
42. Krogh-Madsen,R, Plomgaard,P, Moller,K, Mittendorfer,B, Pedersen,BK:
Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of
IL-18 in humans. Am J Physiol Endocrinol Metab 291:E108-E114, 2006.
43. Lang,CH, Dobrescu,C, Bagby,GJ: Tumor necrosis factor impairs insulin action on
peripheral glucose disposal and hepatic glucose output. Endocrinology 130:4352, 1992.
44. Hotamisligil,GS, Shargill,NS, Spiegelman,BM: Adipose expression of tumor
necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science
259:87-91, 1993.
45. Uysal,KT, Wiesbrock,SM, Marino,MW, Hotamisligil,GS: Protection from obesityinduced insulin resistance in mice lacking TNF-alpha function. Nature 389:610614, 1997.
46. Milstone,LM, Waksman,BH: Release of virus inhibitor from tuberculin-sensitized
peritoneal cells stimulated by antigen. J Immunol 105:1068-1071, 1970.
47. Pacifico,L, Di,RL, Anania,C, Osborn,JF, Ippoliti,F, Schiavo,E, Chiesa,C:
Increased T-helper interferon-gamma-secreting cells in obese children. Eur J
Endocrinol 154:691-697, 2006.
48. Strissel,KJ, Defuria,J, Shaul,ME, Bennett,G, Greenberg,AS, Obin,MS: T-cell
recruitment and Th1 polarization in adipose tissue during diet-induced obesity in
C57BL/6 mice. Obesity (Silver Spring) 18:1918-1925, 2010.

80

49. Yang,H, Youm,YH, Vandanmagsar,B, Ravussin,A, Gimble,JM, Greenway,F,
Stephens,JM, Mynatt,RL, Dixit,VD: Obesity increases the production of
proinflammatory mediators from adipose tissue T cells and compromises TCR
repertoire diversity: implications for systemic inflammation and insulin resistance.
J Immunol 185:1836-1845, 2010.
50. Shiba,T, Higashi,N, Nishimura,Y: Hyperglycaemia due to insulin resistance
caused by interferon-gamma. Diabet Med 15:435-436, 1998.
51. McGillicuddy,FC, Chiquoine,EH, Hinkle,CC, Kim,RJ, Shah,R, Roche,HM,
Smyth,EM, Reilly,MP: Interferon gamma attenuates insulin signaling, lipid
storage, and differentiation in human adipocytes via activation of the JAK/STAT
pathway. J Biol Chem 284:31936-31944, 2009.
52. Simons,PJ, van den Pangaart,PS, Aerts,JM, Boon,L: Pro-inflammatory
delipidizing cytokines reduce adiponectin secretion from human adipocytes
without affecting adiponectin oligomerization. J Endocrinol 192:289-299, 2007.
53. Hogan,JC, Stephens,JM: The identification and characterization of a STAT 1
binding site in the PPARgamma2 promoter. Biochem Biophys Res Commun
287:484-492, 2001.
54. Floyd,ZE, Stephens,JM: Interferon-gamma-mediated activation and ubiquitinproteasome-dependent degradation of PPARgamma in adipocytes. J Biol Chem
277:4062-4068, 2002.
55. Grossberg,SE, Keay,S: The effects of interferon on 3T3-L1 cell differentiation.
Ann N Y Acad Sci 350:294-300, 1980.
56. Keay,S, Grossberg,SE: Interferon inhibits the conversion of 3T3-L1 mouse
fibroblasts into adipocytes. Proc Natl Acad Sci U S A 77:4099-4103, 1980.
57. Yki-Jarvinen,H: Ectopic fat accumulation: an important cause of insulin
resistance in humans. J R Soc Med 95 Suppl 42:39-45, 2002.
58. O'Rourke,RW, White,AE, Metcalf,MD, Winters,BR, Diggs,BS, Zhu,X, Marks,DL:
Systemic inflammation and insulin sensitivity in obese IFN-gamma knockout mice.
Metabolism 61:1152-1161, 2012.
59. Mohamed-Ali,V, Goodrick,S, Rawesh,A, Katz,DR, Miles,JM, Yudkin,JS, Klein,S,
Coppack,SW: Subcutaneous adipose tissue releases interleukin-6, but not tumor
necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196-4200, 1997.
60. Krogh-Madsen,R, Plomgaard,P, Keller,P, Keller,C, Pedersen,BK: Insulin
stimulates interleukin-6 and tumor necrosis factor-alpha gene expression in
human subcutaneous adipose tissue. Am J Physiol Endocrinol Metab 286:E234E238, 2004.

81

61. Lagathu,C, Bastard,JP, Auclair,M, Maachi,M, Capeau,J, Caron,M: Chronic
interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin
resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res
Commun 311:372-379, 2003.
62. Fasshauer,M, Kralisch,S, Klier,M, Lossner,U, Bluher,M, Klein,J, Paschke,R:
Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1
adipocytes. Biochem Biophys Res Commun 301:1045-1050, 2003.
63. Rotter,V, Nagaev,I, Smith,U: Interleukin-6 (IL-6) induces insulin resistance in
3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha,
overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem
278:45777-45784, 2003.
64. Fasshauer,M, Klein,J, Kralisch,S, Klier,M, Lossner,U, Bluher,M, Paschke,R:
Monocyte chemoattractant protein 1 expression is stimulated by growth hormone
and interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 317:598604, 2004.
65. Tsigos,C, Papanicolaou,DA, Kyrou,I, Raptis,SA, Chrousos,GP: Dose-dependent
effects of recombinant human interleukin-6 on the pituitary-testicular axis. J
Interferon Cytokine Res 19:1271-1276, 1999.
66. Klover,PJ, Zimmers,TA, Koniaris,LG, Mooney,RA: Chronic exposure to
interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52:2784-2789,
2003.
67. Klover,PJ, Clementi,AH, Mooney,RA: Interleukin-6 depletion selectively improves
hepatic insulin action in obesity. Endocrinology 146:3417-3427, 2005.
68. Ruderman,NB, Keller,C, Richard,AM, Saha,AK, Luo,Z, Xiang,X, Giralt,M,
Ritov,VB, Menshikova,EV, Kelley,DE, Hidalgo,J, Pedersen,BK, Kelly,M:
Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the
systemic response to exercise and prevention of the metabolic syndrome.
Diabetes 55 Suppl 2:S48-S54, 2006.
69. Kelly,M, Keller,C, Avilucea,PR, Keller,P, Luo,Z, Xiang,X, Giralt,M, Hidalgo,J,
Saha,AK, Pedersen,BK, Ruderman,NB: AMPK activity is diminished in tissues of
IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun
320:449-454, 2004.
70. Matthews,VB, Allen,TL, Risis,S, Chan,MH, Henstridge,DC, Watson,N, Zaffino,LA,
Babb,JR, Boon,J, Meikle,PJ, Jowett,JB, Watt,MJ, Jansson,JO, Bruce,CR,
Febbraio,MA: Interleukin-6-deficient mice develop hepatic inflammation and
systemic insulin resistance. Diabetologia 53:2431-2441, 2010.

82

71. Crandall,DL, Quinet,EM, Morgan,GA, Busler,DE, McHendry-Rinde,B, Kral,JG:
Synthesis and secretion of plasminogen activator inhibitor-1 by human
preadipocytes. J Clin Endocrinol Metab 84:3222-3227, 1999.
72. Alessi,MC, Peiretti,F, Morange,P, Henry,M, Nalbone,G, Juhan-Vague,I:
Production of plasminogen activator inhibitor 1 by human adipose tissue:
possible link between visceral fat accumulation and vascular disease. Diabetes
46:860-867, 1997.
73. Samad,F, Yamamoto,K, Loskutoff,DJ: Distribution and regulation of plasminogen
activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis
factor-alpha and lipopolysaccharide. J Clin Invest 97:37-46, 1996.
74. Takada,Y, Urano,T, Watanabe,I, Taminato,A, Yoshimi,T, Takada,A: Changes in
fibrinolytic parameters in male patients with type 2 (non-insulin-dependent)
diabetes mellitus. Thromb Res 71:405-415, 1993.
75. Mertens,I, Verrijken,A, Michiels,JJ, Van der Planken,M, Ruige,JB, Van Gaal,LF:
Among inflammation and coagulation markers, PAI-1 is a true component of the
metabolic syndrome. Int J Obes (Lond) 30:1308-1314, 2006.
76. Potter van Loon,BJ, Kluft,C, Radder,JK, Blankenstein,MA, Meinders,AE: The
cardiovascular risk factor plasminogen activator inhibitor type 1 is related to
insulin resistance. Metabolism 42:945-949, 1993.
77. Ma,LJ, Mao,SL, Taylor,KL, Kanjanabuch,T, Guan,Y, Zhang,Y, Brown,NJ,
Swift,LL, McGuinness,OP, Wasserman,DH, Vaughan,DE, Fogo,AB: Prevention
of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.
Diabetes 53:336-346, 2004.
78. Shah,C, Yang,G, Lee,I, Bielawski,J, Hannun,YA, Samad,F: Protection from high
fat diet-induced increase in ceramide in mice lacking plasminogen activator
inhibitor 1. J Biol Chem 283:13538-13548, 2008.
79. Eder,C: Mechanisms of interleukin-1beta release. Immunobiology 214:543-553,
2009.
80. Vandanmagsar,B, Youm,YH, Ravussin,A, Galgani,JE, Stadler,K, Mynatt,RL,
Ravussin,E, Stephens,JM, Dixit,VD: The NLRP3 inflammasome instigates
obesity-induced inflammation and insulin resistance. Nat Med 17:179-188, 2011.
81. Fujishiro,M, Gotoh,Y, Katagiri,H, Sakoda,H, Ogihara,T, Anai,M, Onishi,Y, Ono,H,
Funaki,M, Inukai,K, Fukushima,Y, Kikuchi,M, Oka,Y, Asano,T: MKK6/3 and p38
MAPK pathway activation is not necessary for insulin-induced glucose uptake but
regulates glucose transporter expression. J Biol Chem 276:19800-19806, 2001.

83

82. Ling,PR, Bistrian,BR, Mendez,B, Istfan,NW: Effects of systemic infusions of
endotoxin, tumor necrosis factor, and interleukin-1 on glucose metabolism in the
rat: relationship to endogenous glucose production and peripheral tissue glucose
uptake. Metabolism 43:279-284, 1994.
83. Darnell,JE, Jr.: STATs and gene regulation. Science 277:1630-1635, 1997.
84. Zhao,P, Stephens,JM: Identification of STAT target genes in adipocytes.
JAKSTAT 2:e23092, 2013.
85. Harp,JB, Franklin,D, Vanderpuije,AA, Gimble,JM: Differential expression of
signal transducers and activators of transcription during human adipogenesis.
Biochem Biophys Res Commun 281:907-912, 2001.
86. Stephens,JM, Morrison,RF, Pilch,PF: The expression and regulation of STATs
during 3T3-L1 adipocyte differentiation. J Biol Chem 271:10441-10444, 1996.
87. Zhang,K, Guo,W, Yang,Y, Wu,J: JAK2/STAT3 pathway is involved in the early
stage of adipogenesis through regulating C/EBPbeta transcription. J Cell
Biochem 112:488-497, 2011.
88. Yarwood,SJ, Sale,EM, Sale,GJ, Houslay,MD, Kilgour,E, Anderson,NG: Growth
hormone-dependent differentiation of 3T3-F442A preadipocytes requires Janus
kinase/signal transducer and activator of transcription but not mitogen-activated
protein kinase or p70 S6 kinase signaling. J Biol Chem 274:8662-8668, 1999.
89. Shang,CA, Waters,MJ: Constitutively active signal transducer and activator of
transcription 5 can replace the requirement for growth hormone in adipogenesis
of 3T3-F442A preadipocytes. Mol Endocrinol 17:2494-2508, 2003.
90. Nanbu-Wakao,R, Morikawa,Y, Matsumura,I, Masuho,Y, Muramatsu,MA,
Senba,E, Wakao,H: Stimulation of 3T3-L1 adipogenesis by signal transducer and
activator of transcription 5. Mol Endocrinol 16:1565-1576, 2002.
91. Floyd,ZE, Stephens,JM: STAT5A promotes adipogenesis in nonprecursor cells
and associates with the glucocorticoid receptor during adipocyte differentiation.
Diabetes 52:308-314, 2003.
92. Stewart,WC, Pearcy,LA, Floyd,ZE, Stephens,JM: STAT5A expression in Swiss
3T3 cells promotes adipogenesis in vivo in an athymic mice model system.
Obesity (Silver Spring) 19:1731-1734, 2011.
93. Teglund,S, McKay,C, Schuetz,E, van Deursen,JM, Stravopodis,D, Wang,D,
Brown,M, Bodner,S, Grosveld,G, Ihle,JN: Stat5a and Stat5b proteins have
essential and nonessential, or redundant, roles in cytokine responses. Cell
93:841-850, 1998.

84

94. Kawai,M, Namba,N, Mushiake,S, Etani,Y, Nishimura,R, Makishima,M, Ozono,K:
Growth hormone stimulates adipogenesis of 3T3-L1 cells through activation of
the Stat5A/5B-PPARgamma pathway. J Mol Endocrinol 38:19-34, 2007.
95. Balhoff,JP, Stephens,JM: Highly specific and quantitative activation of STATs in
3T3-L1 adipocytes. Biochem Biophys Res Commun 247:894-900, 1998.
96. Fleenor,D, Arumugam,R, Freemark,M: Growth hormone and prolactin receptors
in adipogenesis: STAT-5 activation, suppressors of cytokine signaling, and
regulation of insulin-like growth factor I. Horm Res 66:101-110, 2006.
97. Story,DJ, Stephens,JM: Modulation and lack of cross-talk between signal
transducer and activator of transcription 5 and Suppressor of cytokine signaling-3
in insulin and growth hormone signaling in 3T3-L1 adipocytes. Obesity (Silver
Spring) 14:1303-1311, 2006.
98. White,UA, Coulter,AA, Miles,TK, Stephens,JM: The STAT5A-mediated induction
of pyruvate dehydrogenase kinase 4 expression by prolactin or growth hormone
in adipocytes. Diabetes 56:1623-1629, 2007.
99. Zvonic,S, Story,DJ, Stephens,JM, Mynatt,RL: Growth hormone, but not insulin,
activates STAT5 proteins in adipocytes in vitro and in vivo. Biochem Biophys Res
Commun 302:359-362, 2003.
100. Coulter,AA, Stephens,JM: STAT5 activators modulate acyl CoA oxidase (AOX)
expression in adipocytes and STAT5A binds to the AOX promoter in vitro.
Biochem Biophys Res Commun 344:1342-1345, 2006.
101. Nanbu-Wakao,R, Fujitani,Y, Masuho,Y, Muramatu,M, Wakao,H: Prolactin
enhances CCAAT enhancer-binding protein-beta (C/EBP beta) and peroxisome
proliferator-activated receptor gamma (PPAR gamma) messenger RNA
expression and stimulates adipogenic conversion of NIH-3T3 cells. Mol
Endocrinol 14:307-316, 2000.
102. Hogan,JC, Stephens,JM: The regulation of fatty acid synthase by STAT5A.
Diabetes 54:1968-1975, 2005.
103. Hogan,JC, Stephens,JM: STAT 1 binds to the LPL promoter in vitro. Biochem
Biophys Res Commun 307:350-354, 2003.
104. Zvonic,S, Hogan,JC, Arbour-Reily,P, Mynatt,RL, Stephens,JM: Effects of
cardiotrophin on adipocytes. J Biol Chem 279:47572-47579, 2004.
105. Zvonic,S, Baugh,JE, Jr., Arbour-Reily,P, Mynatt,RL, Stephens,JM: Cross-talk
among gp130 cytokines in adipocytes. J Biol Chem 280:33856-33863, 2005.
106. Tenney,R, Stansfield,K, Pekala,PH: Interleukin 11 signaling in 3T3-L1 adipocytes.
J Cell Physiol 202:160-166, 2005.
85

107. Hogan,JC, Stephens,JM: Effects of leukemia inhibitory factor on 3T3-L1
adipocytes. J Endocrinol 185:485-496, 2005.
108. Stephens,JM, Lumpkin,SJ, Fishman,JB: Activation of signal transducers and
activators of transcription 1 and 3 by leukemia inhibitory factor, oncostatin-M, and
interferon-gamma in adipocytes. J Biol Chem 273:31408-31416, 1998.
109. Hayden,MS, Ghosh,S: Shared principles in NF-kappaB signaling. Cell 132:344362, 2008.
110. Baker,RG, Hayden,MS, Ghosh,S: NF-kappaB, inflammation, and metabolic
disease. Cell Metab 13:11-22, 2011.
111. Tourniaire,F, Romier-Crouzet,B, Lee,JH, Marcotorchino,J, Gouranton,E, Salles,J,
Malezet,C, Astier,J, Darmon,P, Blouin,E, Walrand,S, Ye,J, Landrier,JF:
Chemokine Expression in Inflamed Adipose Tissue Is Mainly Mediated by NFkappaB. PLoS One 8:e66515, 2013.
112. Kim,EK, Choi,EJ: Pathological roles of MAPK signaling pathways in human
diseases. Biochim Biophys Acta 1802:396-405, 2010.
113. Prusty,D, Park,BH, Davis,KE, Farmer,SR: Activation of MEK/ERK signaling
promotes adipogenesis by enhancing peroxisome proliferator-activated receptor
gamma (PPARgamma ) and C/EBPalpha gene expression during the
differentiation of 3T3-L1 preadipocytes. J Biol Chem 277:46226-46232, 2002.
114. Fujishiro,M, Gotoh,Y, Katagiri,H, Sakoda,H, Ogihara,T, Anai,M, Onishi,Y, Ono,H,
Abe,M, Shojima,N, Fukushima,Y, Kikuchi,M, Oka,Y, Asano,T: Three mitogenactivated protein kinases inhibit insulin signaling by different mechanisms in 3T3L1 adipocytes. Mol Endocrinol 17:487-497, 2003.
115. White,UA, Stewart,WC, Mynatt,RL, Stephens,JM: Neuropoietin attenuates
adipogenesis and induces insulin resistance in adipocytes. J Biol Chem
283:22505-22512, 2008.
116. Cowan,SW, Newcomer,ME, Jones,TA: Crystallographic refinement of human
serum retinol binding protein at 2A resolution. Proteins 8:44-61, 1990.
117. Kjeldsen,L, Johnsen,AH, Sengelov,H, Borregaard,N: Isolation and primary
structure of NGAL, a novel protein associated with human neutrophil gelatinase.
J Biol Chem 268:10425-10432, 1993.
118. Flo,TH, Smith,KD, Sato,S, Rodriguez,DJ, Holmes,MA, Strong,RK, Akira,S,
Aderem,A: Lipocalin 2 mediates an innate immune response to bacterial infection
by sequestrating iron. Nature 432:917-921, 2004.

86

119. Goetz,DH, Holmes,MA, Borregaard,N, Bluhm,ME, Raymond,KN, Strong,RK: The
neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with
siderophore-mediated iron acquisition. Mol Cell 10:1033-1043, 2002.
120. Chung,TW, Choi,HJ, Kim,CH, Jeong,HS, Ha,KT: Lipocalin-2 elicited by advanced
glycation end-products promotes the migration of vascular smooth muscle cells.
Biochim Biophys Acta 1833:3386-3395, 2013.
121. Liao,CJ, Li,PT, Lee,YC, Li,SH, Chu,ST: Lipocalin 2 induces the epithelialmesenchymal transition in stressed endometrial epithelial cells: possible
correlation with endometriosis development in a mouse model. Reproduction
2013.
122. Hashikata,A, Yamashita,A, Suzuki,S, Nagayasu,S, Shinjo,T, Taniguchi,A,
Fukushima,M, Nakai,Y, Nin,K, Watanabe,N, Asano,T, Abiko,Y, Kushiyama,A,
Nagasaka,S, Nishimura,F: The inflammation-lipocalin 2 axis may contribute to
the development of chronic kidney disease. Nephrol Dial Transplant 2013.
123. Nocon,AL, Ip,JP, Terry,R, Lim,SL, Getts,DR, Muller,M, Hofer,MJ, King,NJ,
Campbell,IL: The bacteriostatic protein lipocalin 2 is induced in the central
nervous system with West Nile virus encephalitis. J Virol 2013.
124. Jessen,BA, Stevens,GJ: Expression profiling during adipocyte differentiation of
3T3-L1 fibroblasts. Gene 299:95-100, 2002.
125. Yan,QW, Yang,Q, Mody,N, Graham,TE, Hsu,CH, Xu,Z, Houstis,NE, Kahn,BB,
Rosen,ED: The adipokine lipocalin 2 is regulated by obesity and promotes insulin
resistance. Diabetes 56:2533-2540, 2007.
126. Catalan,V, Gomez-Ambrosi,J, Rodriguez,A, Ramirez,B, Silva,C, Rotellar,F,
Gil,MJ, Cienfuegos,JA, Salvador,J, Fruhbeck,G: Increased adipose tissue
expression of lipocalin-2 in obesity is related to inflammation and matrix
metalloproteinase-2 and metalloproteinase-9 activities in humans. J Mol Med
(Berl) 87:803-813, 2009.
127. Wang,Y, Lam,KS, Kraegen,EW, Sweeney,G, Zhang,J, Tso,AW, Chow,WS,
Wat,NM, Xu,JY, Hoo,RL, Xu,A: Lipocalin-2 is an inflammatory marker closely
associated with obesity, insulin resistance, and hyperglycemia in humans. Clin
Chem 53:34-41, 2007.
128. Sommer,G, Weise,S, Kralisch,S, Lossner,U, Bluher,M, Stumvoll,M, Fasshauer,M:
Lipocalin-2 is induced by interleukin-1beta in murine adipocytes in vitro. J Cell
Biochem 106:103-108, 2009.
129. Zerega,B, Cermelli,S, Michelis,B, Cancedda,R, Cancedda,FD: Expression of
NRL/NGAL (neu-related lipocalin/neutrophil gelatinase-associated lipocalin)
during mammalian embryonic development and in inflammation. Eur J Cell Biol
79:165-172, 2000.
87

130. Garay-Rojas,E, Harper,M, Hraba-Renevey,S, Kress,M: An apparent autocrine
mechanism amplifies the dexamethasone- and retinoic acid-induced expression
of mouse lipocalin-encoding gene 24p3. Gene 170:173-180, 1996.
131. Zhang,J, Wu,Y, Zhang,Y, Leroith,D, Bernlohr,DA, Chen,X: The role of lipocalin 2
in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol
22:1416-1426, 2008.
132. Guo,H, Jin,D, Zhang,Y, Wright,W, Bazuine,M, Brockman,DA, Bernlohr,DA,
Chen,X: Lipocalin-2 deficiency impairs thermogenesis and potentiates dietinduced insulin resistance in mice. Diabetes 59:1376-1385, 2010.
133. Law,IK, Xu,A, Lam,KS, Berger,T, Mak,TW, Vanhoutte,PM, Liu,JT, Sweeney,G,
Zhou,M, Yang,B, Wang,Y: Lipocalin-2 deficiency attenuates insulin resistance
associated with aging and obesity. Diabetes 59:872-882, 2010.
134. Jun,LS, Siddall,CP, Rosen,ED: A minor role for lipocalin 2 in high-fat diet-induced
glucose intolerance. Am J Physiol Endocrinol Metab 301:E825-E835, 2011.
135. Guo,H, Bazuine,M, Jin,D, Huang,MM, Cushman,SW, Chen,X: Evidence for the
regulatory role of lipocalin 2 in high-fat diet-induced adipose tissue remodeling in
male mice. Endocrinology 154:3525-3538, 2013.
136. Paton,CM, Rogowski,MP, Kozimor,AL, Stevenson,JL, Chang,H, Cooper,JA:
Lipocalin-2 increases fat oxidation in vitro and is correlated with energy
expenditure in normal weight but not obese women. Obesity (Silver Spring) 2013.
137. Hotamisligil,GS: Molecular mechanisms of insulin resistance and the role of the
adipocyte. Int J Obes Relat Metab Disord 24 Suppl 4:S23-S27, 2000.
138. Kershaw,EE, Flier,JS: Adipose tissue as an endocrine organ. J Clin Endocrinol
Metab 89:2548-2556, 2004.
139. Rocha,VZ, Folco,EJ, Sukhova,G, Shimizu,K, Gotsman,I, Vernon,AH, Libby,P:
Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive
immunity in obesity. Circ Res 103:467-476, 2008.
140. Hotamisligil,GS, Spiegelman,BM: Tumor necrosis factor alpha: a key component
of the obesity-diabetes link. Diabetes 43:1271-1278, 1994.
141. McGillicuddy,FC, Chiquoine,EH, Hinkle,CC, Kim,RJ, Shah,R, Roche,HM,
Smyth,EM, Reilly,MP: Interferon gamma attenuates insulin signaling, lipid
storage, and differentiation in human adipocytes via activation of the JAK/STAT
pathway. J Biol Chem 284:31936-31944, 2009.

88

142. Hu,J, Roy,SK, Shapiro,PS, Rodig,SR, Reddy,SP, Platanias,LC, Schreiber,RD,
Kalvakolanu,DV: ERK1 and ERK2 activate CCAAAT/enhancer-binding proteinbeta-dependent gene transcription in response to interferon-gamma. J Biol Chem
276:287-297, 2001.
143. Peraldi,P, Xu,M, Spiegelman,BM: Thiazolidinediones block tumor necrosis factoralpha-induced inhibition of insulin signaling. J Clin Invest 100:1863-1869, 1997.
144. Vietor,I, Schwenger,P, Li,W, Schlessinger,J, Vilcek,J: Tumor necrosis factorinduced activation and increased tyrosine phosphorylation of mitogen-activated
protein (MAP) kinase in human fibroblasts. J Biol Chem 268:18994-18999, 1993.
145. Nelson,AL, Barasch,JM, Bunte,RM, Weiser,JN: Bacterial colonization of nasal
mucosa induces expression of siderocalin, an iron-sequestering component of
innate immunity. Cell Microbiol 7:1404-1417, 2005.
146. Tan,BK, Adya,R, Shan,X, Syed,F, Lewandowski,KC, O'Hare,JP, Randeva,HS:
Ex vivo and in vivo regulation of lipocalin-2, a novel adipokine, by insulin.
Diabetes Care 32:129-131, 2009.
147. Wen,Z, Zhong,Z, Darnell,JE, Jr.: Maximal activation of transcription by Stat1 and
Stat3 requires both tyrosine and serine phosphorylation. Cell 82:241-250, 1995.
148. Hu,J, Nakano,H, Sakurai,H, Colburn,NH: Insufficient p65 phosphorylation at
S536 specifically contributes to the lack of NF-kappaB activation and
transformation in resistant JB6 cells. Carcinogenesis 25:1991-2003, 2004.
149. Mandrekar,P, Jeliazkova,V, Catalano,D, Szabo,G: Acute alcohol exposure exerts
anti-inflammatory effects by inhibiting IkappaB kinase activity and p65
phosphorylation in human monocytes. J Immunol 178:7686-7693, 2007.
150. Mattioli,I, Sebald,A, Bucher,C, Charles,RP, Nakano,H, Doi,T, Kracht,M,
Schmitz,ML: Transient and selective NF-kappa B p65 serine 536 phosphorylation
induced by T cell costimulation is mediated by I kappa B kinase beta and controls
the kinetics of p65 nuclear import. J Immunol 172:6336-6344, 2004.
151. Mattioli,I, Geng,H, Sebald,A, Hodel,M, Bucher,C, Kracht,M, Schmitz,ML:
Inducible phosphorylation of NF-kappa B p65 at serine 468 by T cell
costimulation is mediated by IKK epsilon. J Biol Chem 281:6175-6183, 2006.
152. Vermeulen,L, De,WG, Van,DP, Vanden Berghe,W, Haegeman,G: Transcriptional
activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein
kinase-1 (MSK1). EMBO J 22:1313-1324, 2003.
153. Zhao,P, Stephens,JM: STAT1, NF-kappaB and ERKs play a role in the induction
of lipocalin-2 expression in adipocytes. Mol Metab 2:161-170, 2013.

89

154. Grandaliano,G, Valente,AJ, Rozek,MM, Abboud,HE: Gamma interferon
stimulates monocyte chemotactic protein (MCP-1) in human mesangial cells. J
Lab Clin Med 123:282-289, 1994.
155. Zhong,H, SuYang,H, Erdjument-Bromage,H, Tempst,P, Ghosh,S: The
transcriptional activity of NF-kappaB is regulated by the IkappaB-associated
PKAc subunit through a cyclic AMP-independent mechanism. Cell 89:413-424,
1997.
156. Varinou,L, Ramsauer,K, Karaghiosoff,M, Kolbe,T, Pfeffer,K, Muller,M, Decker,T:
Phosphorylation of the Stat1 transactivation domain is required for full-fledged
IFN-gamma-dependent innate immunity. Immunity 19:793-802, 2003.
157. Zhu,X, Wen,Z, Xu,LZ, Darnell,JE, Jr.: Stat1 serine phosphorylation occurs
independently of tyrosine phosphorylation and requires an activated Jak2 kinase.
Mol Cell Biol 17:6618-6623, 1997.
158. Wojciak,JM, Martinez-Yamout,MA, Dyson,HJ, Wright,PE: Structural basis for
recruitment of CBP/p300 coactivators by STAT1 and STAT2 transactivation
domains. EMBO J 28:948-958, 2009.
159. Buss,H, Dorrie,A, Schmitz,ML, Hoffmann,E, Resch,K, Kracht,M: Constitutive and
interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is
mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha},
IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase
1 (TBK1), and an unknown kinase and couples p65 to TATA-binding proteinassociated factor II31-mediated interleukin-8 transcription. J Biol Chem
279:55633-55643, 2004.
160. Mujico,JR, Baccan,GC, Gheorghe,A, Diaz,LE, Marcos,A: Changes in gut
microbiota due to supplemented fatty acids in diet-induced obese mice. Br J Nutr
110:711-720, 2013.
161. Wu,GD, Chen,J, Hoffmann,C, Bittinger,K, Chen,YY, Keilbaugh,SA, Bewtra,M,
Knights,D, Walters,WA, Knight,R, Sinha,R, Gilroy,E, Gupta,K, Baldassano,R,
Nessel,L, Li,H, Bushman,FD, Lewis,JD: Linking long-term dietary patterns with
gut microbial enterotypes. Science 334:105-108, 2011.
162. Katsuda,S, Okada,Y, Okada,Y, Imai,K, Nakanishi,I: Matrix metalloproteinase-9
(92-kd gelatinase/type IV collagenase equals gelatinase B) can degrade arterial
elastin. Am J Pathol 145:1208-1218, 1994.
163. Unal,R, Yao-Borengasser,A, Varma,V, Rasouli,N, Labbate,C, Kern,PA,
Ranganathan,G: Matrix metalloproteinase-9 is increased in obese subjects and
decreases in response to pioglitazone. J Clin Endocrinol Metab 95:2993-3001,
2010.

90

164. Blaise,S, Romier,B, Kawecki,C, Ghirardi,M, Rabenoelina,F, Baud,S, Duca,L,
Maurice,P, Heinz,A, Schmelzer,CE, Tarpin,M, Martiny,L, Garbar,C, Dauchez,M,
Debelle,L, Durlach,V: Elastin-derived peptides are new regulators of insulin
resistance development in mice. Diabetes 62:3807-3816, 2013.

91

APPENDIX. COPYRIGHTS RELEASE PERMISSIONS
Appendix 1. Copyright release for Chapter 2

92

Appendix 2. Copyright release for Chapter 3
This research was originally published in Journal of Biological Chemistry. Zhao P, Elks
CM and Stephens JM. The induction of lipocalin-2 protein expression in vivo and in vitro.
J Biol Chem 289:5960-5969, 2014. © the American Society for Biochemistry and
Molecular Biology

93

VITA
Peng Zhao was born in May 1986, in Kaifeng, Henan Province, P.R. China. Peng
grew up in Kaifeng and graduated from Kaifeng Senior Middle School in 2004. He
began his undergraduate study majoring in Biological Science in the fall of 2004 at
Henan University. In July of 2008, Peng graduated with a Bachelor of Science from
Henan University. In the fall of 2009, he entered the graduate program in the
Department of Biological Science at Louisiana State University as a doctoral student
under the mentorship of Dr. Jacqueline M. Stephens. Peng will graduate with a Doctor
of Philosophy degree in Biological Sciences in May of 2014.

94

